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Abstract 
 
The brain derived neurotrophic factor holds neuroprotective and neurogenic roles. The 
presence of this factor is believed to present highly beneficial effects on injured cells within 
several neurological disorders, where the levels of this neurotrophin are usually drastically 
decreased. Neural stem cells are multipotent, self-renewing cells with the ability to differentiate 
into the three main type of cells within the central nervous system - neurons, astrocytes and 
oligodendrocytes. The combination of gene therapy, through the introduction of therapeutic 
genes into the desired cells, with cell therapy aiming for the replacement of damaged cells 
within a given disorder, hold great promise in modern regenerative medicine. 
The aim of this work was the overexpression of the brain derived neurotrophic factor in neural 
stem cells. For this, mouse and human neural stem cells were transfected with one of three 
non-viral techniques - microporation, lipid and cationic-polymer based strategies. Human NSC 
were efficiently transfected using the commercial lipid-based transfection reagent Lipofectamine 
2000 with an efficiency of 35%, maintaining their differentiation potential. Cells within the 
differentiation process were efficiently transfected with 13% efficiency. Cell viability has always 
remained above 70% after the lipofection process. The transfection with the BDNF gene 
resulted in neurons with longer primary neurites, and more secondary neurites than control 
cells, which hints at the promotion of neurite outgrowth and ramification of neurons by this 
neurotrophin. 
Finally, healthy cells were exposed to toxic concentrations of glutamate. Conditioned media 
containing secreted BDNF from transfected cells was able to protect these cells from glutamate-
induced neurotoxicity, as well as reducing the levels of expression of the pro-apoptotic protein 
caspase7 to near-control levels. 
Overall, this work provides the first evidences of the successful use of BDNF-overexpressing 
NSC, based on a non-viral gene delivery approach for decreasing neurotoxicity.  
 
 
Keywords 
Neural Stem Cells; Brain Derived Neurotrophic Factor; Non-viral gene delivery; Lipofection; 
Plasmid DNA; Neurotoxicity 
 
 
 
VII 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VIII 
 
Resumo 
 
O trabalho proposto tinha por objectivo a sobre-expressão do “Brain derived neurotrophic 
factor” (BDNF) em células estaminais neurais. O BDNF é um factor neurotrófico com papéis 
neuroprotectores e neurogénicos. Este encontra-se drasticamente sub-expresso numa 
variedade de desordens neurológicas. Acredita-te que a sobre-expressão de BDNF seja 
benéfica para as células afectadas em determinado nicho in vivo. 
São consideradas células estaminais neurais, aquelas que apresentam multipotência; a 
capacidade de auto-renovação; e o potencial para diferenciar em um dos três grandes tipos de 
células presentes no sistema nervoso central - neurónios, astrócitos e oligodendrócitos. 
A simbiose entre terapia génica, através da introdução de genes em células de interesse, e a 
terapia celular, visando a substituição de células lesadas em consequência de determinada 
patologia, detém um enorme potencial e uma esperança renovada na área da medicina 
regenerativa moderna.  
Células estaminais neurais de ratinho e humanas foram transfectadas através de um de 3 
métodos não-virais - microporação, lipofeção e transfeção com base em polímeros catiónicos. 
A utilização do reagente de transfecção lipídico Lipofectamina 2000 permitiu notavelmente 
transfectar uma linha de células estaminais neurais humanas com uma eficiencia de 35%, 
mantendo o potencial de diferenciação da cultura intacto.  Ainda, células durante o processo de 
diferenciação foram transfectadas com cerca de 13% de eficiência. Em todos os casos foi 
mantida uma viabilidade celular superior a 70% após o processo de lipofeção.  
Um resultado promissor sugeriu que a presença de BDNF promoveu a ramificação de 
neurónios, potenciando ainda o crescimento de neuritos primários em relação ao controlo. 
Foi ainda possível fazer uma análise dos efeitos neuroprotectores do BDNF, pela exposição de 
uma cultura diferenciada a concentrações tóxicas de glutamato. A presença de BDNF 
secretada pelas células transfectadas, permitiu a proteção da cultura por parte de 
neurotoxicidade induzida pelo glutamato, mantendo uma actividade celular superior ao 
controlo, e sendo ainda responsável pela redução apreciável do nível de actividade da proteína 
pro-apoptótica caspase7 para níveis semelhantes aos do controlo, sugerindo uma prevenção 
de eventos de morte celular programada. 
Este trabalho fornece as primeiras evidências da utilização eficaz de células estaminais neurais 
a sobre-expressar BDNF, utilizando métodos não-virais de entrega de genes para a prevenção 
e redução dos mecanismos de neurotoxicidade induzidos pelo glutamato. 
Palavras-chave 
Células estaminais neurais; Brain Derived Neurotrophic Factor; Entrega não-viral de genes; 
Lipofeção; Plasmídeo; Neurotoxicidade 
IX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Index 
 
Acknowledgements ...................................................................................................................... IV 
Abstract ........................................................................................................................................ VI 
Keywords .................................................................................................................................. VI 
Resumo ...................................................................................................................................... VIII 
Palavras-chave ....................................................................................................................... VIII 
Index .............................................................................................................................................. X 
List of figures ............................................................................................................................... XII 
List of tables ............................................................................................................................ XVIII 
List of abbreviations ................................................................................................................... XX 
1. Introduction ................................................................................................................................ 2 
1.1 Stem Cells ........................................................................................................................... 2 
1.1.1 - Embryonic stem cells ................................................................................................. 3 
1.1.2 - Adult stem cells .......................................................................................................... 3 
1.2 - Neural Stem Cells in the Central Nervous System ........................................................... 4 
1.2.1 - Sources of Neural Stem Cells ........................................................................................ 6 
1.2.2 - Phenotype and morphology ........................................................................................... 7 
1.2.3 - Neural Stem Cell culture in vitro .................................................................................... 8 
1.2.4 - Differentiation of Neural Stem Cells ............................................................................. 13 
1.2.5 - Applications of Neural Stem Cells ................................................................................ 15 
1.3 - Neurotrophic factors ............................................................................................................ 17 
1.3.1 - The role of the Brain derived neurotrophic factor ........................................................ 18 
1.4 - Gene Therapy ..................................................................................................................... 20 
1.4.1 - Viral methods ............................................................................................................... 22 
1.4.2 - Non-viral methods ........................................................................................................ 22 
1.4.3 - Gene delivery to the Central Nervous System ............................................................. 24 
2. Materials and Methods ............................................................................................................ 27 
2.1 Bacterial strains and plasmid DNA .................................................................................... 27 
2.2 BDNF amplification by PCR .............................................................................................. 27 
2.3 BDNF cloning into pcDNA3.1 ............................................................................................ 28 
2.4 Transformation of bacterial strains .................................................................................... 29 
2.5 Neural Stem Cell culture ................................................................................................... 30 
2.5.1 Cell lines ..................................................................................................................... 30 
2.5.2 Expansion of Neural Stem Cells................................................................................. 30 
2.5.3 Differentiation of Neural Stem Cells ........................................................................... 31 
2.6 Neural Stem Cell transfection ............................................................................................ 32 
XI 
 
2.6.1 Microporation .............................................................................................................. 32 
2.6.2 Cationic polymer-based transfection .......................................................................... 33 
2.6.3 Lipid-based transfection ............................................................................................. 33 
2.7 Flow cytometry .................................................................................................................. 34 
2.8 Immunocytochemistry ....................................................................................................... 34 
2.9 Alamar blue assay ............................................................................................................. 34 
2.10 Qualitative analysis of neuronal neurites by ImageJ® software ..................................... 35 
2.11 Quantification of mRNA extracts by real time PCR ......................................................... 36 
2.12 Statistical analysis ........................................................................................................... 38 
3. Results & Discussion ............................................................................................................... 40 
3.1 - Amplification of BDNF by PCR........................................................................................ 40 
3.2 - Cloning of BDNF into pcDNA3.1 ..................................................................................... 40 
3.3 - Transfection of mouse Neural Stem Cells ...................................................................... 42 
3.3.1. Microporation ............................................................................................................. 42 
3.3.2. Cationic polymer-based transfection ......................................................................... 44 
3.3.3. Lipofection ................................................................................................................. 46 
3.4. Transfection of human neural progenitor cells ................................................................. 47 
3.4.1. Microporation ............................................................................................................. 47 
3.4.2. Lipofection ................................................................................................................. 49 
3.5. BDNF effect on the differentiation of ReN cells................................................................ 57 
3.6. Qualitative analysis of neurites by ImageJ® software ..................................................... 59 
3.7. Glutamate toxicity evaluation by the Alamar blue assay .................................................. 61 
3.8. mRNA quantification by RT-PCR ..................................................................................... 62 
4. Conclusion and future trends .................................................................................................. 70 
5. References .............................................................................................................................. 73 
Appendix ................................................................................................................................... XXII 
 
 
 
 
 
XII 
 
List of figures 
Figure 1.1 - Schematic representation of self-renewal and differentiation potential of stem cells. 
Taken from 
1
.  
 
Figure 1.2 - Interactions between the three cell types of the CNS - neurons, astrocytes and 
oligodendrocytes. Taken from 
2
. 
 
Figure 1.3  - Schematic representation of neural stem cell based therapy. Adapted from 
3
. 
 
Figure 1.4 - human immortalized Neural Stem Progenitor cell population. Scale bar is 50μm. 
 
Figure 1.5 - Neural stem cells and lineage-commited cell markers. Taken from
4
. 
 
Figure 1.6 - Neural stem cell culture methods: neurosphere formation and adherent monolayer. 
Taken from
5
. 
 
Figure 1.7 - Schematic representation of the two main types of gene based therapy: Direct 
delivery, and cell-based delivery.  Adapted from
6
. 
 
Figure 2.3.1  -  pcDNA3.1-BDNF (A) and pcDNA3.1-GFP (B) plasmid maps, containing the 
respective BDNF and GFP genes. The most important elements of the plasmid are displayed: 
the CMV promoter; T7 promoter binding site; multiple cloning sites (MCS); BGH polyadenilation 
signals (BGH pA); SV40 promoter and origin; EM7 promoter; Zeocyn resistance marker; SV40 
polyadenilation signal (SV40 pA) and ampicilin resistance marker. 
 
Figure 2.10 - Sequence of operations performed on ImageJ® until a final binarized image is 
achieved, following neurite measurement of NeuronJ plugin. 
 
Figure 3.1 - Confirmation of efficient BDNF gene (741bp) amplification by PCR on a 1% 
agarose gel. LIII is the DNA Ladder III (NZYtech®). 
 
Figure 3.2.1 - Confirmation of the correct plasmid constructions on a 1% agarose gel. The 
samples are presented in their non-digested form (ND); single digestion with BamHI (BI) and 
HindIII (HI) and double digested with the pair BamHI/HindIII (BI/HIII) and HindIII/ApaI (HI/AI) for 
pcDNA3.1-BDNF and pcDNA3.1-GFP, respectively. LIII corresponds to the DNA ladder III 
(NZYtech®). 
 
XIII 
 
Figure 3.3.1 - CGR8-NS cells microporated using 1 pulse of 1500V for 20ms, and 0.5μg of 
pcDNA3.1-GFP. Cell viability for transfected and control cells (A), and cell recovery of 
transfected cells (B). Values were calculated based on mean ± SD of 4 to 6 countings of 2 
replicates. 
 
Figure 3.3.2 - CGR8-NS cells microporated using 1 pulse of 1500V for 20ms, and 0.5μg of 
pcDNA3.1-GFP or pcDNA3.1-BDNF. Cell viability of transfected and control cells (A) and cell 
recovery of control cells (B) on days 2 and 4. Values were calculated based on the mean ± SD  
of 4 to 6 cell countings of 2 replicates. 
 
Fig. 3.3.3 - CGR8 cells transfected with TurboFect, using a 2:1 TF:DNA ratio (μL/μg) for each 
reaction. Cell viability, recovery and transfection efficiency is presented for each protocol 
performed. Cell viability and recovery were calculated based on the mean value ± SD of 2 cell 
coutings from 3 replicates. Percentage of GFP+ cells is the mean value ± SD of 3 replicates. 
 
Fig 3.3.4 - CGR8-NS cells transfected with Lipofectamine® 2000 under different LF/DNA ratios. 
Cell viability is shown for each ratio and for LF quantities alone (A). Cell recovery and 
transfection efficiency (B). Cell viability and recovery were calculated based on the mean ± SD 
of 3 independent cell countings from 2 replicates each. Percentage of GFP
+
 cells is the value of 
one experiment.  
 
Figure 3.3.5 - Fluorescence images of CGR8 cells transfected with lipoplexes of several 
LF/DNA ratios. Brighfield images can be seen on the left. GFP-expressing cells can be seen (in 
green) on the right side of the panel. 
 
Figure 3.4.1 - ReN cells microporated using 0.5µg of pcDNA3.1-GFP under several conditions. 
Cell viability and recovery are calculated based on the mean ± SD of 3 cell countings from 2 
replicates. Percentage of GFP
+
 are the value of one experiment for each condition. The 
conditions are characterized by the voltage (V), length of pulse(s) (ms) and number of pulses 
(p). 
 
Fig 3.4.2 - ReN cells transfected with Lipofectamine® 2000 complexed with either pcDNA3.1-
GFP or pcDNA3.1-BDNF (2μL/1μg). Cell viability, recovery and percentage of GFP
+
 cells for 
day 1 (A) and day 3 (C). Fluorescence images of transfected ReN cells, by day 1 (B) and day 3 
(D).  Values are presented as the mean of 4 to 6 independent coutings from 2 replicates ± SD. 
Percentage of GFP+ cells is presented as the mean of 2 replicates ± SD. 
 
Figure 3.4.3 - ReN cells transfected with Lipofectamine® 2000. One day after transfection, 
differentiation of the culture was induced. Cell viability, recovery and percentage of GFP+ cells 
on day 1 (A) and day 12 (B) of differentiation.  Dot-plots of flow cytometry analysis of ReN cells 
XIV 
 
transfected with GFP, acquired on day 1 and 12 of differentiation, using a wider gate (C). 
Histograms based on the previously presented dot-plots (D). Cell viability and recovery was 
calculated based on the mean value ± SD of 3 independent countings from 3 replicates each. 
GFP+ cells is presented as the mean ± SD of 2 replicates. 
 
Figure 3.4.4 - ReN cells transfected with Lipofectamine® 2000. One day after transfection, 
differentiation of the culture was induced. Cell viability, recovery and percentage of GFP+ cells 
on day 1 (A) and day 12 (B) of differentiation.  Dot-plots of flow cytometry analysis of ReN cells 
transfected with GFP, acquired on day 1 and 12 of differentiation, using a smaller gate (C). 
Histograms based on the previously presented dot-plots (D). Cell viability and recovery was 
calculated based on the mean value ± SD of 3 independent countings from 3 replicates each. 
GFP+ cells is presented as the mean ± SD of 2 replicates. 
 
Figure 3.4.5 - ReN cells within 4
th
 of differentiation were transfected with Lipofectamine 2000. 
Cell viability, recovery and GFP+ cells (A). Cell viability and recovery was calculated based on 
the mean value ± SD of 3 independent countings from 3 replicates each. GFP+ cells is 
presented as the mean ± SD of 2 replicates. Fluorescence microscopy picture of differentiating 
transfected cells (B).  Dot-plots of flow cytometry analysis of differentiating ReN cells transfected 
with GFP, acquired  day 4 of differentiation, using a wide gate (C). Histograms based on the 
previously presented dot-plots (D). 
 
Figure 3.4.6 - ReN cells within 4
th
 of differentiation were transfected with Lipofectamine 2000. 
Cell viability, recovery and GFP+ cells (A). Cell viability and recovery was calculated based on 
the mean value ± SD of 3 independent countings from 3 replicates each. GFP+ cells is 
presented as the mean ± SD of 2 replicates. Fluorescence microscopy picture of differentiating 
transfected cells (B).  Dot-plots of flow cytometry analysis of differentiating ReN cells transfected 
with GFP, acquired  day 4 of differentiation, using a small gate (C). Histograms based on the 
previously presented dot-plots (D). 
 
Figure 3.5.1 - Immunostaining of non-differentiated ReN cells. Neuronal cell marker Tuj1 and 
neural stem/progenitor cells marker Nestin are shown in red. The nuclear counter-stain DAPI in 
blue. Merged images are shown at the right. Scale bar is 50μm. 
 
Figure 3.5.2 - Immunostaining of ReN cells transfected with BDNF and differentiated under 
standard conditions (A-D, M-O); non-transfected ReN cells differentiated with supplemented 
exogenous BDNF (E-H) and non-transfected ReN cells differentiated under standard conditions 
(I-L, P-R). The markers Tuj1 and Nestin are shown in red, GFAP in green and the nuclear 
counter-stain DAPI in blue. Scale bar is 50μm 
 
XV 
 
Figure 3.6.1 - Differentiated ReN cells cultured in either normal differentiation conditions 
(control), with supplemented BDNF (exo-BDNF) or transfected ReN cells with BDNF (pcDNA-
BDNF) were immunostained against neuronal-marker Tuj1. Fluorescence microscopy images 
were analyzed and mean length of primary neurites (A) and  secondary neurites (B) were 
measured in each condition.  Results are displayed as the mean ± SD of 19 independent 
measurements (n=19). Statistical differences are indicated with * for p < 0.05. 
 
Figure 3.7.1 - Relative fluorescence intensity at different time-points of differentiated ReN cell 
cultures exposed to different glutamate concentrations (A), and to 4mM glutamate and 3-day old 
conditioned medium (B). Values are the mean ± SD of 2 replicates. 
 
Figure 3.8.1 - Relative fold-increase in gene expression of several genes in BDNF-transfected 
cells (compared to non-transfected cells), on days 1 and 3. Results are displayed for cell 
markers Nestin, GFAP, β3-tubulin and Sox2 on day 1 (A) and day 3 (B), for BDNF (C) and IL-6 
(D). Values are the mean relative gene expression normalized with respect to endogenous 
GAPDH. Duplicates were run on * marked samples. 
 
Figure 3.8.2 - RT-PCR reaction products on days 1 (A) and 3 (B). The DNA ladders used were 
the 500bp ladder (Lonza®) and the HyperLadder 50bp (Bioline®), respectively. 
 
Figure 3.8.3 - Relative fold-increase in gene expression of several genes in glutamate-exposed 
cells (Glu) and cells incubated with conditioned-media after glutamate exposure (Glu+BDNF) 
(compared to non-exposed  control cells), at the 12
th
 day of differentiation. Results are displayed 
for Caspase7 (A), BDNF (B) and β3-tubulin (C). Values are the mean relative gene expression 
normalized with respect to endogenous GAPDH. Duplicates were run on * marked samples. 
 
Figure 3.8.4 - Agarose gel of the RT-PCR reaction products. The DNA ladder used was the 
HyperLadder 50 bp (Bioline®). 
 
Supplementary figure S1 - Sequencing results, showing 738 matching nucleotides, confirming 
correct cloning of the desired gene into the pcDNA3.1 plasmid. BDNF nucleotide sequence is 
highlighted in blue. 23 nucleotides are missing in the sequencing results due to incomplete 
sequencing. By using a reverse primer with a sequence downstream of BDNF we were able to 
confirm the correct type of the initial base pairs. Both primers were designed by the company 
StabVida® according to the type of plasmid in use (pcDNA3.1). The obtained sequence 
perfectly matched with the sequence showed below that was provided by the supplier company 
(Origene®). 
 
Supplementary figure S2 - Flow cytometry profiles of the ReN cells transfected with GFP at 
different time points, using the wider gate.   
XVI 
 
 
Supplementary figure S3 - Flow cytometry profiles of the ReN cells transfected with GFP at 
different time points, using the smaller gate.   
 
Supplementary figure S4 - Fold-increase in BDNF expression at the 3
rd
 day of culture, using a 
Ct of 23.3 (A) or a Ct of 18.8 (B). Both Ct values were returned in the same experiment within 
one sample, although none were used to prevent an inaccurate analysis. 
Supplementary figure S5 - Fold-increase in IL-6 expression at the 1
st
 day of culture, using a Ct 
of 38.3 (A) or a Ct of 32.6 (B). Both Ct values were returned in the same experiment within one 
sample, although none were used to prevent an inaccurate analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XVII 
 
 
 
 
 
 
 
XVIII 
 
List of tables 
 
Table I - Primers used in mRNA quantification by real-time PCR. 
 
Table II - Concentration of plasmids obtained after purification with the Endotoxin-free 
NucleoBond® Xtra Midi EF kit, and purity assessment through ratios of absorbance at different 
wavelengths. Concentration and purity of plasmid DNA is presented as the mean value ± SD of 
three independent measurements. 
XIX 
 
 
XX 
 
List of abbreviations 
 
AD Alzheimer´s disease 
ALS Amyotrophic lateral sclerosis 
ASC Adult stem cells 
BBB Blood brain barrier 
BDNF Brain Derived Neurotrophic Factor 
BGH Bovine Growth Hormone 
BI BamHI 
BLAST Basic Local Alignment Search Tool 
BMP Bone morphogenetic protein 
BPs Basal progenitors 
bp Base pairs 
cDNA Complementary DNA 
CMV Cytomegalovirus immediate early promoter 
CNS Central Nervous System 
CNTF Cilliary neurotrophic factor 
Ct Cycle threshold 
D Digested 
DA Dopaminergic 
DAPI 4',6-diamidino-2-phenylindole 
DMEM/F-12 Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 
DMSO Dimethyl sulfoxide  
EB Embryoid body 
ECM Extracellular Matrix 
EGF Epidermal Growth Factor 
ERK Extracellular signal Regulated Kinase 
exo-BDNF Exogenous BDNF 
ESC Embryonic Stem cells 
FACS Fluorescence Activated Cell Sorting 
FCS forward-scattered light  
FGF2 Fibroblast Growth Factor 
GABA Gamma amino butyric acid 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GDNF Glial-cell-line-Derived Neurothrophic Factor 
GFAP Glial Fibrillary Acidic Protein 
GFP Green Fluorescent Protein 
Glu Glutamate 
XXI 
 
hBDNF Human Brain Derived Neurotrophic Factor 
hESC Human embryonic stem cells 
hMSC Human mesenchymal stem cells 
hNSC Human neural stem cells 
HIII HindIII 
HSC Hematopoietic stem cells 
HT Huntington´s disease 
ICM Inner cell mass 
IL-6 Interleukin-6 
ILF Insulin-like growth factor 
iPSC Induced Pluripotent Stem Cells 
JAK– STAT Janus-activated kinase–signal transducer and activator of transcription pathway 
LB Luria Broth 
LF Lipofectamine 2000 
LIF Leukemia Inhibitor Factor 
LII Ladder II 
LIII Ladder III 
MAPK Mitogen Activated Protein Kinase 
mBDNF Mouse Brain Derived Neurotrophic Factor 
MCS Multi-Cloning Site 
MSC Mesenchymal stem cells 
ND Non-Digested 
NEPs Neuroepithelial progenitors 
NGF Nerve Growth Factor 
NGS Normal goat serum 
NMDA N-methyl-D-aspartate 
NPC Nuclear Pore Complexes 
NSC Neural Stem Cells 
NTs Neurothrophic Factors 
NT-4/5 Neurotrophin-4/5 
NV Non-Viable Cells 
OB Olfactory bulb 
PBS Phosphate-Buffered Saline 
PD Parkinson´s disease 
PDGF Platelet derived growth factor 
PEG-PEI polyethylene glycol-polyethyleneimine  
RMS Rostral migratory stream 
PCR Polymerase Chain Reaction 
PFA Paraformaldehyde 
PILs PEGylated immunoliposomes 
XXII 
 
PolyA Polyadenilation signal 
RB Resuspension Buffer 
RG Radial glia 
RT-PCR Reverse Transcription Polymerase Chain Reaction 
S/MAR Scaffold/Matrix Attachment Region 
SCID-X1 X-linked severe combined immunodeficiency 
SD Standard deviation 
SGZ Sub-Granular Zone 
Shh Sonic hedgehog 
siRNA Small interfering RNA 
SSC Side-scattered light  
SVZ Sub-Ventricular Zone 
T3 3,3,5-tri-iodothyronine 
TF TurboFect 
TLR9 Toll-Like Receptor 9 
Trks Tyrosine Kinases 
TuJ1 Neuron-specific class III β-tubulin 
VC Viable cells 
WHO World Health Organization
 
 
 
2 
 
1. Introduction  
 
1.1 Stem Cells 
 
A stem cell is an undifferentiated cell with the ability to self-renew, i.e. of reproducing itself, as 
well as the ability to give rise to specialized and functional cells through differentiation
1,7
 (Figure 
1.1)  
This last property renders stem cells a great value in regenerative medicine, being the ultimate 
goal the possibility of providing sufficient specialized cells for the replacement of lost or 
damaged cells due to a certain injury or disease.  
 
 
Figure 1.1 - Schematic representation of self-renewal and differentiation potential of stem cells. Taken 
from 
1
.  
 
The self-renewal of stem cells can occur in two distinct ways: (1) through symmetric cell 
division, which is a proliferative type division in which one single cell originates two daughter 
cells genetically identical to the progenitor or (2) through assymetrical division where one cell 
originates an identical daughter cell and a cell of a different type with distinct genetic properties. 
The later cell division is a differentiative type division, giving rise to specialized cells as well as 
maintaining a pool of pluripotent cells
7,8
. 
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1.1.1 - Embryonic stem cells 
 
In humans, embryonic stem cells (ESC) can be found in the inner cell mass (ICM) of the pre-
implantation blastocyst (4-5 days)
7,9
. This ICM is responsible for the development of the three 
embryonic germ layers conducting to the formation of the human body - the endoderm 
(responsible for generating pancreatic and liver cells); the mesoderm (leading to 
cardiomyocytes, skeletal muscle and smooth muscle) and the ectoderm (neurons, epithelial 
cells and glial cells)
1,7
. Unlike adult stem cells (ASC), ESC are considered pluripotent cells since 
they are able to give rise to all tissues of the adult organism
10
. Cultivation of these cells in vitro 
is a common procedure nowadays, and can be achieved through well-established culture 
conditions. This makes ESC tremendously helpful in the creation of disease models, through 
the study of specific drug-targeting systems, and from a basic developmental stem cell biology 
standpoint.  
Some concerns still arise from the use of these cells for in vivo cell therapy, including that the 
proliferative properties required for proper expansion of these cells may trigger the formation of 
tumors, or give rise to cell types different than those required, or even triggering an immune 
response in the host
1
. Also, some drawbacks concerning the low efficiency and time required for 
cells to differentiate into the cell type required greatly hamper its broader use in cell therapy
10
. 
 
Immunogenic rejection of allogeneic cells led to extensive research aiming at fulfilling the need 
for successfully accepted cells by the host. In this sense, in 2005 adult fibroblasts were 
successfully reprogrammed to an ESC state, by fusion with ESC
11
.  On another approach, 
Yamanaka and colleagues successfully reprogrammed adult fibroblasts into a pluripotent state, 
by introducing only four factors - Oct3/4, Sox2, c-Myc and Klf4
12
. These cells, then termed 
induced pluripotent stem cells (iPSC), are similar to human ESC in terms of gene expression 
and capacity of specific differentiation
9
. 
Following this approach, somatic cells from a certain individual could be subjected to in vitro 
reprogramming to a prior pluripotent state, and proceed to differentiation to the proper cell type 
required, avoiding the organism´s rejection of those same cells
13
. 
 
 
1.1.2 - Adult stem cells 
 
Numerous types of stem cells exist in the adult organism. These are commonly referred to as 
adult stem cells. They comprise lineage committed cells residing in specific sites in the different 
tissues of the adult organism, and are able to give rise only to the cell type of the tissue or organ 
where they are localized, being responsible for the regeneration of those same tissues upon 
injury, or as the natural replacement of older cells, as reviewed elsewhere
1
. Mesenchymal stem 
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cells (MSC) are adult stem cells, which were first isolated from the bone marrow
14
, although it is 
now known that these can also be obtained from other niches such as adipose tissue
15
 and 
umbilical cord blood
16
 and matrix
17
. MSC can differentiate into fibroblasts, chondrocytes, 
osteoblasts and adipocytes, being responsible for the regeneration of bone and cartilaginous 
tissues such as tendons and ligaments. Hematopoietic stem cells (HSC) are found in the bone 
marrow and umbilical cord blood, being responsible for the development of blood lineage cells. 
Cardiac stem cells support myocardial regeneration, and have been shown to differentiate into 
functional myocardium when injected into an ischemic heart
18
. Also in the liver, stable amounts 
of hepatic stem cells remain throughout life, giving rise to mature hepatocytes
19
. Neural stem 
cells are localized in well defined zones of the adult brain and are responsible for the generation 
of neurons, astrocytes and oligodendrocytes. The latter type of stem cells is the focus of this 
thesis, so these will be addressed in more detail later (section 1.3).  
 
Adult stem cells present several clinical advantages regarding their lower potential of 
differentiation when compared to embryonic stem cells, originating a finite number of cell types, 
which ultimately decreases their malignant potential
20
. 
 
 
1.2 - Neural Stem Cells in the Central Nervous System 
 
A neural stem cell can be defined as an uncommitted cell able to give rise to all three major cell 
types of the Central Nervous System (CNS) - neurons, astrocytes and oligodendrocytes, and it 
must have the capacity for self-renewal
9
. The former property renders NSC the concept of 
multipotent cells, suggesting the potential they hold for generating more than one possible cell 
type. They are radial astrocyte-like, nestin-positive cells
9,21
. 
 
The development of the vertebrate CNS begins with a neural plate consisting of a single layer of 
neuroepithelial progenitor cells (NEPs)
5,22,23
. Upon folding, this layer gives rise to a neural tube 
containing also NEPs, which later on give rise to both radial glia (RG) and basal progenitors 
(BPs)
5
. A significant amount of RG is present in primary cell populations from CNS tissue, and 
they are believed to be a good source of neural stem cells. Basal progenitors are neuronal-
restricted cells, and can be generated both by RG and NEPs. In the mammalian brain, neural 
stem cells are believed to exist within two neurogenic niches - the subventricular zone (SVZ) of 
the lateral ventricle and the subgranular zone (SVG) of the dentate gyrus
5,24
. Besides neural 
stem cells, those neurogenic niches comprise glial cells, ependymal cells, extracellular matrix 
(ECM) components and proteoglycans
9
. 
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Oligodendrocytes are glial cells necessary to the proper development of the brain and neuronal 
functioning, through the myelin formation around the neurons axons
25
 (figure 1.2). They are 
produced throughout the entire CNS
9,26,27
. Myelin is a membranous structure rich in lipids with 
low water content, which isolates the nerve electrical signals transmitted through axons. This 
structure is implicated in many neurological disorders, as in Multiple Sclerosis, caused by the 
demyelinization of neurons
25
, i.e. loss of myelin in the neurons. 
Oligodendrocytes and other glial cells are established early at the time of neurogenesis, 
although their maturation occurs mainly in the early post-natal stage. 
 
 
Figure 1.2 - Interactions between the three cell types of the CNS - neurons, astrocytes and 
oligodendrocytes. Taken from 
2
. 
 
Astrocytes are the most abundant cells within the CNS, and are generated throughout the entire 
system
9,26,27
. These star-like cells are responsible for a wide variety of tasks including axonal 
guidance, synaptic support and regulation of the blood brain barrier and overall blood flow
28
. 
Through the secretion of growth factors important to proper axon growth and stable synaptic 
activity they modulate the microenvironment of adjacent neurons
28
. Glial cells, including 
astrocytes and oligodendrocytes constitute 90% of the total cells in the adult brain
25
. 
 
At last, the generation of new neurons is mainly restricted to the SVZ of the lateral ventricle and 
SVG of the dentate gyrus. Newly formed neuroblasts migrate through the rostral migratory 
stream (RMS) mainly composed of astrocytes, finally reaching the olfactory bulb (OB), where 
they migrate outwardly as isolated cells, later on maturating into differentiated neurons
8,24
. 
Neurons are highly differentiated cells responsible for the transmission of electrical signals 
throughout the entire nervous system that regulate every impulse and response in the 
organism. The brain contains a wide variety of neuronal cell types, such as motor neurons, 
responsible for making the connection between brain signals and muscle movement; sensory 
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neurons, which allow the body to perceive external stimuli from peripheral cells such as 
epithelial cells, and sending the signal to the spinal cord or the brain. Others tend to specialize 
in the generation and release of neurotransmitters for proper cell-cell communication. A cortical 
neuron makes up around 10,000 connections with other brain cells. This gives up the 
complexity of the neuronal network, and allows to realize the reason why the brain, especially 
the human cortex, is the core for the development of human learning, memory creation and 
overall rational thinking
29-31
. 
 
It is still unclear the extent to which multipotent stem cells exist in the CNS and what really 
defines them, so this renders the concept of neural stem cell quite an abstract meaning to it. 
Nonetheless, several stem/progenitor cells have been identified in the neurogenic niches in the 
brain, which, depending on the microenvironment signals, ultimately have the capacity to 
generate the supportive glial type of cells, or one of the neuronal lineages found in the adult 
intricate neuronal network
26
.  So, a neural stem cell can be considered the one capable of self-
renewal, although not necessarily for unlimited divisions, and of course, being able to give rise 
to neurons and glial cells as stated before
1,5
. 
 
1.2.1 - Sources of Neural Stem Cells 
Neural stem cells can be found in several tissues or can derived through differentiation of other 
cells (figure1.3).  
 
Figure 1.3  - Schematic representation of neural stem cell based therapy. Adapted from 3. 
7 
 
 
Since the work of Ramón y Cajal in 1928
32
, it was believed that the brain did not have the ability 
to generate new neurons. Nevertheless, this theory has been proven wrong since neurogenesis 
is an active process that occurs throughout life
27,33
. The two main regions responsible for this 
phenomenon, which are as well the main sources of adult percursors are the subgranular zone 
(SGZ) of the dentate gyrus in the hippocampus and in the subventricular zone (SVZ) of the 
lateral ventricles
26,27,33
. In 1992 the first adult and fetal NSC from the central nervous system of 
rodents were isolated
34
. A few years later, in 1998 the same was accomplished with human 
NSC
35,36
.  
 
The isolation procedure of NSC is based on the dissection and further dissociation of fetal 
tissue, following plating on the adequate conditions. Weiss and Reynolds managed to perform 
this by plating the cells from adult mice striata in culture-medium supplemented with epidermal 
growth factor (EGF)
34
. A few years later, the same was achieved with human cells. Flax and 
colleagues dissociated cells from the human fetal telencephalon, which were then cultured in 
medium containing fibroblast growth factor (FGF2) and/or EGF. This provided some insight 
about the nature of cells isolated from human fetal tissue, and the fact that in that case, those 
cells showed neural stem cell properties, being able to proliferate in vitro.  
 
NSC can also be obtained by differentiation from other cell types, as described in the section 
1.2.3 “Neural Stem Cells culture in vitro”.  
 
 
1.2.2 - Phenotype and morphology 
NSC are star-like cells with the ability to adhere to culture-grade plastic (figure 1.4). 
 
Figure 1.4 - Human immortalized neural progenitor cell population. Scale bar is 50μm. 
 
NSC characterization remains a topic with no consensus within the scientific community. 
According to literature, there is not yet a single marker that characterizes NSC exclusively and 
so can be used to selectively identify and isolate these cells
4
. Considering this, usually the 
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characterization is achieved by the combination of several cell-specific markers such as nestin, 
Sox1/2, Pax6 and CD133
4
 (figure 1.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 - Neural stem cells and lineage-commited cell markers. Taken from
4
. 
 
Nestin is an intermediate filament
8,34
 that distinguishes neuroepithelial stem cells from other 
differentiated cells in the neural tube
25
. Sox2 is expressed in a variety of cells within the SVZ, 
being in part responsible for the maintenance of an undifferentiated proliferative state during 
development
37
. Pax6 is a transcription factor that also maintains the stemness of the culture, 
promoting asymmetric divisions
8
. CD133 is a marker for the transmembrane protein prominin-1, 
found in the apical plasma membrane of NSC
8
. The assessment of the expression of these 
markers is usually achieved through several techniques such as flow cytometry and quantitative 
real time PCR.  
 
Upon assessment of differentiation capacity of NSC, usually cells which acquire neuron 
morphology are identified by the expression of several markers such as the microtubule 
associated protein 2 (MAP-2); β-tubulin III, a protein that is primarily expressed in neurons and 
is involved in axon guidance and maintenance
38
; substance P, a neurotransmitter that belongs 
to the small peptides group of neurokinins responsible for affective behavior, and the main 
inhibitory neurotransmitter GABA (gamma amino butyric acid) markers
34
. Cells with 
oligodendrocytic characteristics express cell-surface protein O4, and astrocytes are mainly 
distinguished through the expression of the glial fibrillary acidic protein
39
. 
 
1.2.3 - Neural Stem Cell culture in vitro 
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NSC can either proliferate in vitro, maintaining their multipotent state or differentiate into specific 
cell types. The maintenance of proliferative capacity and differentiative potential can be 
promoted by the addition of growth factors to the culture, such as EGF and fibroblast growth 
factor 2 (FGF2)
8,21,40
. The withdrawal of these growth factors leads to a mixed culture of 
neurons, astrocytes and oligodendrocytes
9
.  But like any other stem cell, neural stem cells need 
the appropriate conditions to differentiate into the proper cell-type required, which is usually 
achieved by the withdrawal of mithogens or by the exposure to differentiative factors. EGF is 
normally used for astrocytic lineage commitment, although it plays a major role in maintaining 
the stemness properties of a population
39
, with functions in the most important stages of the 
regulation of cell growth, proliferation and differentiation
41
. It is a proliferative factor not only for 
neural stem cells, but for mammalian cells in general, acting through binding to the EGF-
receptor. It is involved in several signaling pathways such as the Mithogen activated protein 
kinases/Extracellular signal regulated kinases (MAPK/ERK) which ultimately promotes cell 
survival
42
. FGF-2 is one of the major players in neural development. It is implicated in the 
induction and patterning of mesoderm and neural tissues in vertebrate embryos
41
. It is also 
responsible for the proliferation and survival of early forebrain neural precursors, also by playing 
a role in the MAPK signaling pathway
40,41,43
. 
 
A culture of NSC can be maintained in vitro through the supplementation of culture medium with 
both EGF and FGF-2, or EGF alone. The withdrawal of EGF from the medium, leads to 
neuronal differentiation and apoptotic events, mediated by FGF-2
37
. 
 
One can distinguish two major in vitro culture methods for NSC: neurosphere formation or 
adherent culture
44
. Neurospheres can be understood as spherical clusters of undifferentiated 
neural stem cells
44,45
 (figure 1.6). Weiss and Reynolds were the first to report culturing 
conditions to expand neural stem cells isolated from the adult mouse brain, using the 
neurosphere approach
46
. The cells from adult mice striata were dissociated enzymatically and 
plated in EGF containing medium without any other substrates or adhesive factors. After 6-8 
days, clusters of cells could be observed. On a parallel assessment, it was observed that no 
proliferation events occurred upon EGF withdrawal, once more reinforcing its role in multipotent 
state maintenance. The cells from the cluster were dissociated and replated on polyornithine 
coated dishes, in order to assess the ability of these cells to generate new neurospheres again 
in the presence of EGF. Secondary neuroshperes were indeed observed, and the majority of 
cells within it expressed nestin. The withdrawal of EGF once more inhibited the proper 
expansion of cells
46
. Meanwhile other works reported the generation of neurospheres on low-
attachment tissue culture plastic dishes
46
, with medium containing FGF2 besides EGF, and by 
6-8 days of culture, clusters of cells with 100-150μM are expected to form, although karyotypic 
instability is known to occur from the tenth passage and forth
5
. This approach has some 
advantages, as its tridimensional structure allows for relevant cell-cell and cell-matrix 
interactions, mimicking the in vivo niche where these cells are found, making it physiologically 
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interesting
44
. On the other hand, layers of cells are formed in a stratified manner, with 
differentiated cells at the core of the cluster under suboptimal conditions, leaving the precursors 
cells more exposed to the environment
5
, being limiting in terms of diffusion of essential nutrients 
and oxygen
47
. Alterations in differentiative and proliferative patterns have also been identified, 
as well as chromosomal instability
44
. The three-dimensional structure of the clusters also makes 
it hard to identify the different cells, as the highly heterogeneous population greatly hampers the 
study of multipotentiality of single-cells. Another major drawback resides in the fact that 
neurospheres differentiate preferentially into astrocytes rather than neurons, in vitro, making it 
less interesting from the therapeutical standpoint
44
.  
 
 
 
Figure 1.6 - Neural stem cell culture methods: neurosphere formation and adherent monolayer. Taken 
from
5
. 
 
Another method is based on the growth of cells on an adherent or monolayer culture, using 
ECM components
44
 and growth factors such as EGF and FGF-2
5
. The culture flasks are usually 
coated with fibronectin, a component of various types of ECM suitable for cell adhesion and 
proliferation
41
,  or laminin, another substrate commonly used in the coating of culture dishes
41,48
. 
The latter interacts with the β1 integrins receptors present in NSC surface, which in vivo is 
responsible for the activation of a signaling pathway that maintains these cells in the CNS
41,44
. 
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Conti and colleagues induced differentiation of neural precursors from ES-derived cells in an 
adherent monolayer. The precursors were plated in a basal medium containing supplementation 
with N2 (including insulin, which is known to promote differentiation of ESC as well as favoring 
differentiated cells survival), eliminating any commited or differentiating cell, with either FGF-2 
alone, or combining FGF-2 and EGF. It was observed that FGF-2 alone did not allow for cell 
growth, but the combination of both mitogens led to proliferation of precursor cells expressing 
nestin, without expressing any glial or neuronal lineage markers
21
. 
Withdrawal from EGF resulted in death of a great number of cells as well as initiating 
differentiation events, even though observing that laminin would ensure cell viability upon EGF 
withdrawal. Removal of FGF-2 from the medium led to differentiation of 30-40% of the 
population to neuronal commited cells expressing type III β-tubulin, MAP2 and NeuN, while 
maintaining self-renewing NSC
21
. 
This system minimizes spontaneous differentiation, and its niche independence makes the cells 
more responsive to the specific factors in the media, which may lead to more homogeneous and 
defined cell populations
5
. 
 
Nonetheless, it seems that the specific roles of EGF and FGF-2 still remain somewhat unclear.  
A  lot of evidence supports that long-term propagation of NSC requires both factors
5
. On the 
other hand, from the early work of Reynolds and Weiss, evidence suggests that EGF alone is 
capable of providing efficient renewal of this cells
34
. The more recent work of Conti and 
colleagues also supports this approach, stating that while both factors are required for 
derivation of NSC from ESC, only EGF is necessary to support the established ES-derived NSC 
line, playing the major roles mainly through the suppression of apoptosis
49
.  
 
Embryonic Stem Cell-derived NSC 
 
As mentioned before, apart from the direct isolation from tissues, neural stem cells can also be 
obtained through the differentiation of other cell types. 
For instance, NSC can be derived from ESC. As mentioned in section 1.2, embryonic stem cells 
are pluripotent cells derived from pre-implantation embryos, and can be maintained in that 
pluripotent state in vitro. ESC are prone to spontaneous differentiation upon withdrawal from the 
supportive pluripotency agents. However, withdrawal of these molecules often results in a 
heterogeneous culture of mixed cells
41
. For neural lineage restriction, the adequate growth 
factors must be provided. The neural differentiation of hESC can be achieved with 2 distinct 
models: as an embryoid body (EB) model, in which cells are allowed to grow freely on 
suspension promoting random differentiation, and then selecting required cells for plating on 
neural proliferation medium; or as an adherent culture, where cells are subjected to neural 
differentiation from the start, along with coating or co-culturing with feeder layers, which are 
later on removed and proliferation medium is added for continuous growth
50,51
. 
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Some well-established culture conditions are available nowadays. For instance, Pollard et al 
have shown that ESC can be propagated in vitro by the addition of the leukemia-inhibition factor 
(LIF) and the bone morphogenetic protein (BMP) (known to block neural differentiation of ESC). 
Upon removal of these factors, some of these cells readily give rise to NEPs expressing Sox1. 
Finally the generation of Sox2-positive neural stem cells can be achieved by the addition of the 
mitogens EGF and FGF-2
49,52
. 
 
Conti and colleagues were able to derive neural precursors from several embryonic stem cell 
lines, including the CGR8 cell line
21
, which has been first derived in the laboratory of Professor 
Austin Smith, Wellcome Trust Centre for Stem Cell Research (Cambridge, United Kingdom), 
deriving the CGR8-NS cell line also used in this work. Neural precursors were derived from ESC 
by culturing these cells in serum-free medium. After a week, cells were re-plated in basal 
medium in the presence of FGF-2 alone or FGF-2 plus EGF. This allowed for the selection of 
differentiating cells only. Clusters of cells were formed, which were then dissociated and re-
plated on fresh medium. Bipolar cells were generated, able to proliferate in EGF and FGF-2-
containing medium. These cells expressed immature neural marker nestin, among others, while 
lacking expression of astrocytic and neuronal specific markers and maintaining diploid 
chromosome content at late passages. This led the authors to suggest the generated cells 
present self-renewing neural stem cell behavior
21
. 
 
ESC can provide bigger quantities of fully defined populations of neural progenitors and 
differentiated cells. Hence, models of neurodegenerative diseases can be more readily created 
by the insertion of defined mutations on differentiated cells
50
. 
 
Induced-Pluripotent Stem Cell-derived NSC 
 
Besides ESC, iPSCs can be used to obtain NSC in vitro. The derivation of iPSCs may 
circumvent some of the issues related to the rejection of cells upon allogeneic transplants
9
. 
Being a relatively new field little is known about the specific mechanisms of action, although 
some studies have aroused interest in the scientific community. Some well-characterized 
protocols are available to guide the differentiation of iPS cells to neural progenitors, neurons, 
and other CNS cells
41
. 
 
Once the generation of iPSC is achieved, the neural differentiation of ESC can usually be 
applied to these cells as well. Tipically, the cells are initially treated with BMP inhibitors
53
 or they 
can be co-cultured with stromal cell lines. From this point, three possible methods are 
employed.  One of them consists in neural induction by Noggin treatment. This molecule is the 
antagonist of BMP, and is known to increase neurogenesis by blocking gliogenesis through a 
negative feedback mechanism
26
, being also responsible for the upregulation of expression of 
neural markers such as Pax6, Sox2 and Nestin
41
. Another method is based on co-culturing with 
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PA6 stromal cells. These are loose connective tissue cells found in several organs such as the 
bone marrow. They provide matrix-support for other cells
41
. The surface of these cells 
undergoes activities known to promote neural differentiation
54
. Another alternative carries out 
culturing of cells on a defined media with a laminin substrate
47,55,56
. All three methods are 
capable of generating early neural progenitors expressing neural stem cell markers, such as 
Pax6, Sox1 and/or Sox2. These progenitors can be maintained as neurospheres and then 
further differentiated to mature neurons or glia
41
. 
 
One of the well-characterized procedures for generation of iPSC-derived NSC has been 
described by Onorati and colleagues
57
. iPSC were first generated from mice fibroblasts as 
described elsewhere
13
. These cells were later on cultured on neural induction media 
supplemented with B27. After 12 days, mitogens EGF and FGF-2 were added. Aggregates 
were generated in the following days, from which were later on derived monolayers of the iPSC-
derived neural stem cells, expressing the appropriate markers for NSC, presenting stability for 
more than 60 passages. Furthermore, successful differentiation was achieved, demonstrating 
the ability of these iPSC-derived NSC to give rise to neurons, astrocytes and 
oligodendrocytes
57
. 
 
The design of robust and well-characterized protocols for neural differentiation from iPS cells is 
of the utmost importance to a successful cell therapy approach. With this, somatic cells from the 
patient can be retrieved, and through the adequate reprogramming to a pluripotent state, the 
desired cell lineage can be generated in order to provide the CNS cells lost during the disease. 
 
1.2.4 - Differentiation of Neural Stem Cells 
 
The basis for neural stem cell differentiation seems to be the withdrawal of the proliferative 
factors EGF and FGF-2. This renders a rather mixed culture of several cell types as stated 
before. This is possible by the intrinsic capacity of NSC, and all stem cells for that matter, to 
start differentiating in vitro when the proliferative agents are removed from the medium. That 
approach can be advantageous for different cell-cell interactions study and for providing a more 
similar model of the real and diversified in vivo environment. Nonetheless, for fundamental stem 
cell biology, a rather pure population of the desired cell type is preferred. 
 
For instance, Donato et al have described a differentiation protocol addressing the human 
neural stem cells used in this work (ReN cell VM)
58
. The differentiation is achieved by exposing 
a confluent population to medium without growth factors. Within as little as four days, rounded 
cell bodies possessing long neurites were achieved, reinforcing the belief that withdrawal of 
mitogens is the simplest method for generation of a differentiated neural stem cells culture
58
. 
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Another optimized protocol for differentiation of ES-derived NSC into a homogenous neuronal 
population has been designed by Spiliotopoulos and colleagues
59
, having used among others, 
the ES-derived NS cell line CGR8-NS, also used throughout this work. The approach is based 
on the culture of NSC in media containing FGF-2. The withdrawal of this factor causes 
widespread cell death, but promotes the survival of the differentiating cells. Later on, the cells 
are cultured in equal composition media with the addition of BDNF.  From that point, a gradual 
increase in BDNF and decrease in FGF-2 concentration renders a homogeneous mature 
neuronal population
59
. Other reports state that a neuronal fate can be achieved firstly by 
removal of the proliferative factors. Then, the addition of the platelet-derived growth factor 
(PDGF) generates neuronal-lineage restricted cells, by increasing the expression of neuron-
specific markers such as MAP2 and β3-tubulin
39
 and by activating the MEK-RSK-C/EBP 
pathway, that is believed to be essential for neurogenesis
55
. Finally, it has been suggested that 
FGF2 and the neurotrophin-3 (NT3) lead to cell cycle exit and neuronal differentiation. 
Concerning neurons in particular, and the high degree of variability of neuronal types within the 
CNS, one must consider that different types of neurons require different factors for proper 
differentiation. For example, cortical pyramidal neurons usually require sonic hedgehog (Shh) 
signaling
53
, a crucial molecule in the development and patterning of the nervous system
60
 
whereas interneurons (responsible for coordinating motor response
61
) seem to require 
retinoids
61
. The more suitable protocol will ultimately differ with the outcome pretended and 
overall work objectives. 
 
Astrocytes can be obtained by the exposure of NSC to the cilliary neurotrophic factor (CNTF) in 
the presence of EGF, which will act via the JAK– STAT (Janus-activated kinase–signal 
transducer and activator of transcription) gliogenic pathway
55,62
. 
 
Although oligodendrocyte differentiation protocols are not as well established as neuronal and 
astrocytic lineages, a relatively recent work has provided new insights about this matter. A 
population containing 20% of mature myelinating oligodendrocytes has been achieved firstly by 
culturing cells in media containing growth factors FGF-2 and PDGF, and forskolin, after which 
cells with small condensed bodies and short processes could be observed. Subsequent factor 
withdrawal and addition of 3,3,5-tri-iodothyronine (T3) and ascorbic acid  leads to a mixed 
population of oligodendrocytes (20%), astrocytes (40%) and neurons (10%). Functional 
validation of oligodendrocytes was performed, being these able to re-myelinate severely 
impaired mice models
63
. 
 
During differentiation, NSC reorganize their transcriptome, leading to the silencing of 
multipotency genes, while up-regulating genes involved in lineage-commitment
26
. However, this 
is not perfectly understood, and so, there seems not to be a singular approach in the 
differentiation of the desired type of cell. This may due to the high degree of uncertainty that still 
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exists regarding the specific roles of growth factors and differentiating agents, and the outcome 
resulting from their interaction.  
 
 
 
1.2.5 - Applications of Neural Stem Cells 
 
Neural stem cells find application in a wide variety of scientific areas ranging from the 
fundamentals of stem cell developmental biology, through its applications in the pharmaceutical 
industry as drug screening platforms, to the clinical applications where gene and cell therapy 
are used in modern regenerative medicine. Some relevant clinical applications in the field of 
neurological disorders therapy are described further in this section. 
 
Besides the obvious tragic impact neurological disorders have on patients and their families, 
taking away nearly 7 million people every year, an outstanding economic impact arises from 
these diseases. In Europe only, almost 140 billion euros were spent on this matter, states a 
2007 World Health Organization (WHO) report
64
. From this striking data, it is easy to 
acknowledge the imperative need to pursue more effective and accessible means to treat these 
types of illnesses, sparing millions from suffering and creating a healthier, well-informed 
community that will also save up great amounts of money in the long run. 
 
Although the brain has capacity to regenerate damaged tissue, this phenomenon is quite 
limited
33
. For that reason, bioprocessing is required in order to provide additional sources of 
cells and tissue capable of restoring the damage caused by innumerous diseases
65
. A 
successful stem cell-based therapy for neurological disorders must aim at the replacement of 
the lost cells in the disease process, and in the integration of these cells into the cortical 
circuitries
66
. A great deal of neurological disorders such as the ones described below has 
already been addressed by stem-cell therapy, with promising outcomes. 
 
Parkinson´s disease (PD) is responsible for the loss of dopaminergic neurons
66,67
. One of the 
therapeutical approaches involves the delivery and upregulation of neurotrophic factors, the 
generation of endogenous dopamine as well as implantation of supportive cells and 
dopaminergic neurons. An encouraging study provides proof of principle that nigrostriatal 
dopamine neurons can replace cells lost to this disease, and provide long-term recovery of 
motor function
68
. Amyotrophic Lateral Sclerosis (ALS) is a highly restrictive disease that results 
in the progressive disfunction and degeneration of motor neurons in cerebral cortex, brain stem 
and spinal cord. Stem cell therapy seems to have step into this disease with several good news. 
Transplanted NSC have reduced astrogliosis and inflammation events, ameliorating the overall 
symptoms of ALS
69
. This is believed to be due, in part, to the capacity of these cells to produce 
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and release trophic factors
69
.  Another finding suggests that fetal motor neurons grafted to the 
adult rat spinal cord migrate to the correct zone and generate functional connection with skeletal 
muscle 
70,71
. Some of the consequences of Alzheimer´s disease (AD) include decreased 
synaptic integrity  and widespread neuronal loss ultimately leading to cognitive and memory 
impairment
68
. A study from Esmaielzade and colleagues demonstrated that epidermal neural-
crest neural stem cells were capable of migrating to the host tissue and survive, generating both 
neuron and astrocyte-like cells in an in vivo rat model of AD
72
. Huntington´s disease (HT) is 
characterized by the loss of a specific class of neurons - projection neurons, which results in 
progressive dementia in the affected persons
73
. Nerve growth factor (NGF)-producing neural 
stem cells have been shown to protect striatal neurons against a induced excitotoxic damage, 
demonstrating that the supply of neurotrophic factors by genetically modified NSC may be a 
viable option in the treatment of these illnesses
74
. 
 
Also in brain tumors, NSC seem to play a promising role. It has been demonstrated that neural 
stem cells implanted into the brain migrate towards the tumoral region. These cells can then be 
used as delivery agents, whereas the localized secretion of numerous molecules such as anti-
tumoral drugs may provide a successful alternative to highly invasive treatments
75
. 
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1.3 - Neurotrophic factors 
 
The growth and survival of developing neurons in the CNS as well as the maintenance of 
mature neurons is dependent on the presence of the so-called neurotrophic factors, herein 
called neurotrophins (NTs). These molecules constitute a wide family of proteins with different 
signaling pathways with the ultimate goal of sustaining neurite outgrowth, neuronal cell 
differentiation and survival, and overall network construction
76
. There are 109 ongoing clinical 
trials with neurotrophic factors (as listed by clinicaltrials.gov on July 23
rd
 2013). 
 
The neurotrophin family is mainly composed by the nerve growth factor (NGF) which is the best 
characterized member of all, the brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-
3) and neurotrophin-4/5 (NT-4/5). Two more members have been identified, NT-6 and NT-7 
although only detected in fish and are believed not to have human homologues
77
. Moreover, a 
few polypeptides show neurotrophic properties, although not being considered members of the 
family for structural reasons
77
. These include ciliary neurotrophic factor (CNTF), glial cell line-
derived neurotrophic factor (GDNF), insulin-like growth factor (ILF) and basic fibroblast growth 
factor (bFGF2)
78,79
. 
 
NTs play their roles through the interaction with two main types of receptors. One is the tyrosine 
kinase receptor family (Trks), activated by the mature neurotrophin forms, responsible for 
mediating receptor dimerization and transphosphorylation of activation loop kinases
62
. The most 
relevant members of this family are TrkA/B/C. TrkA is responsible for binding NGF, while  BDNF 
and NT-4/5 bind tightly to TrkB and NT-3 interacts with TrkC
62,80
. Besides this, a lower-affinity 
receptor called p75 binds all neurotrophins and is implicated in neurotransmitter release and cell 
death
81,82
 as well as being responsible for deciding which neurons survive during development, 
through complex signaling
77
. 
Binding of NTs triggers the activation of the Trk receptors firstly by ligand-induced receptor 
dimerization, and then by autophosphorilation of tyrosine residues inside the cells. The 
activation of certain binding proteins leads to activation of the MAPK pathway and 
phosphorilation of extracellular signal-regulated kinases (ERKs) which results in the promotion 
of survival, proliferation and differentiation of NSC
62
. 
 
NTs present clear clinical advantages. In certain neuronal disorders there seems to be a 
diminished expression of some viability and neuronal functionality markers. Neurotrophic factors 
can be of extreme importance in these cases, holding great promise in the therapy of 
neurodegenerative disorders, owing to their neuroprotective properties
79
. Nevertheless, despite 
all the invaluable effects that these molecules present, the use of neurotrophins for the 
treatment of CNS disorders still presents major issues due to the restricted pharmacokinetics 
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and bioavailability properties of the proteins and also to their inability to cross the blood-brain-
barrier
83
. Cell-based therapy may provide a better route to deliver lower doses of neurotrophic 
factors, by maintaining a tight regulation of gene expression. Several successful cases are 
described in the next section, where genetically modified cells are able to migrate to injured 
sites and replace, regenerate or up-regulate certain genes in damaged cells. 
  
1.3.1 - The role of the Brain derived neurotrophic factor 
 
BDNF is a member of the NT family, and plays major roles in neuronal development through the 
interaction with TrkB as mentioned above. A total of 65 ongoing clinical trials regarding BDNF 
are listed (as in clinicaltrials.gov on July 23
rd
 2013), implicated in a wide variety of neurological 
disorders. 
 
Neuronal plasticity refers to the capacity of the brain to adapt when faced with environmental 
stress, through the formation of new synapses or the generation of new neurons
76
. BDNF is 
highly expressed in regions of the brain responsible for neuronal plasticity, and is a crucial 
mediator in this process, showing a regulated expression when altered neuronal function 
occurs
76
. Ma and colleagues showed that the induction of BDNF and activation of its 
intracellular receptors can produce neural regeneration, reconnection, and dendritic sprouting, 
improving synaptic efficacy in conditions of traumatic brain injury
84
. In fact, a study on the 
localization of TrkB receptor suggests that the synapses are the main site of action of BDNF in 
the CNS 
85
. However, BDNF alone has been shown to fail to act as a survival factor for neuronal 
precursors, and was not capable to prevent their death overtime
86
, suggesting that more factors 
may be needed in order to maintain a proper neural circuitry.  This is supported by the fact that 
BDNF along with NT-4/5 has been shown to influence the survival and differentiation of 
neurons, through a retrograde manner leading to the upregulation of Acetylcholine and 
neuregulin
82
. 
 
BDNF is regulated in multiple ways. Glial cells present truncated forms of TrkB receptors, 
modulating its availability through the regulated storage and release of the active protein
80
. 
Hormones also influence BDNF expression, where for example glutamate receptor agonists 
induce, whereas GABA receptor agonists inhibit its expression
80
. It exerts its neuroprotective 
properties through blocking of apoptosis. Lee and colleagues demonstrated that BDNF-
overexpressing cells down-regulate the expression of proapoptotic proteins such as p53, p21 
and caspase 3, as well as up-regulating the anti-apoptotic protein Bcl-2 and cell surviving-
promoting protein Akt1
87
. It mediates differentiation and survival of NSC in neuroshperes 
through the activation of its receptors in the cells, and activating several pathways such as 
ERK-1/2 neurogenic pathway; AKT, which supports neuronal survival and prevents apoptosis, 
and STAT-3, associated with proliferation of NSC as well as directing its differentiation into 
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glia
62
. BDNF-overexpressing NSC have been shown to stimulate synaptic protein expression 
and promote functional recovery following transplantation in rat model of traumatic brain injury
84
. 
In another study, it was shown they significantly improve neurological motor function compared 
to native NSC upon transplantation after traumatic brain injury, although 4 weeks after the 
transplantation that difference was no longer observed
84
. 
 
It has also been demonstrated that BDNF is crucial in the recovery of AD and PD. Under stress 
conditions, BDNF mRNA seems to have a diminished expression
80
. For instance, NSC have 
been shown to improve certain complex neuronal circuitry through the action of BDNF, that 
showed reduced activity due to AD
88
. Increased levels of hippocampal BDNF were reported as 
the main reason for the regain of cognitive function, providing solid negative controls 
demonstrating that BDNF knockdown in transplanted NSC failed to improve the condition and 
even reduced synaptic density after transplantation
88
. In PD as well, decreased levels of 
expression of this neurotrophin are observed
89
. Nevertheless, this is not true for all conditions, 
since after seizures, BDNF mRNA expression is greatly hampered, with the same profile being 
detected in cases of patients with temporal lobe epilepsy
90
. 
 
An interesting finding hypothesizes its implication in neurotransmitter communication, through 
autocrine loops and paracrine interactions between neighbor cells and communication from 
dendrites to axon terminals
85
. Through these interactions, it may promote survival and recovery 
upon injury, as well as regulate the function of synapses and dendritic arbor modeling
80
, which 
may be the basis of all of BDNF´s highly protective and regenerative properties. 
 
Summing up, BDNF exerts highly beneficial and constructive effects owing to its essential 
regulatory role in the survival and differentiation of various neural cell types during brain 
development and after injury, being arguably the most promising of all neurotrophic agents in 
the management of brain traumatic injury
84
. This encourages its use as a therapeutic agent in 
CNS disorders, either through the functional protein form, although direct infusion of the protein 
has some major limitations
84
, or by the ex-vivo modification of cells, which has shown to be a 
promising approach. 
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1.4 - Gene Therapy 
 
Gene therapy functions a lot like conventional drug therapy, except in this case the “drug” 
administered is a therapeutic gene to be taken up by the cells, which will then express it. The 
gene introduced will code for a protein whose production was either completely lost, or 
dramatically decreased as a consequence of a certain metabolic disorder. Or in other cases, the 
gene produces a totally new protein in the target cells envisaging the bypassing of a certain 
metabolic pathway.  The therapeutic molecule, such as the gene of interest is usually packaged 
into a bigger molecule generally called a vector, which presents properties that facilitate the 
modification of the target tissue or organ. There are numerous kinds of vectors, ranging from 
relatively simple plasmid vectors to complex macromolecular aggregates of polymers and 
nucleic acids. Those will be described in greater detail further in the text. 
 
There are two main types of gene based therapy. One consists in the direct delivery of the 
therapeutic gene packaged within a vector, into the target tissue or organ through a variety of 
methods. Another type of genetic therapy consists in the ex-vivo modification of cells by the 
vector containing the therapeutic agent
6
. When appropriate expansion of the required modified 
cells is reached, the administration to the patient can finally be accomplished (figure 1.7). 
 
 
Figure 1.7 - Schematic representation of the two main types of gene based therapy: Direct delivery, and 
cell-based delivery.  Adapted from
6
. 
 
A successful gene therapy approach must fulfill some fundamental criteria, circumventing 
several imposing barriers. Specifically, in cell-based delivery, intracellular barriers comprise the 
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overall mechanism of vector uptake by cells and gene expression, which includes the adequate 
interaction between the vector and the surface of the target cell, successful diffusion through the 
cytoplasm and finally entering the nucleus. The internalization into the target cell is a critical 
step, especially in the delivery of plasmid DNA (pDNA) since its negative overall charge will 
suffer electrostatic repulsion from the cell membrane
91
. In electroporation-based methods this is 
avoided, through the momentaneous depolarization of the membrane
92,93
. Upon internalization, 
the vectors that entered the cell by endocytosis must escape lysosomal degradation. 
Lysossomes are enclosed vesicles with a high nuclease content and low pH, being the cell 
compartment responsible for the degradation of internalized molecules
91
. Both liposomes and 
polymers have been shown to escape lysosomal degradation, through the disruption of the 
lysosome membrane
91
. The diffusion of pDNA through the cytosol may be troublesome due to 
the presence of nucleases that degrade unprotected DNA
92,93
. Finally, the nuclear envelope is 
interrupted by big proteic structures called nuclear pore complexes (NPC) that regulate the 
traffic of molecules into the nucleus. These allow ions to flow freely into the nucleus but will 
retain proteins larger than 60kDa and nucleic acids bigger than 300bp
92
. A relevant approach is 
based on the transfection of highly proliferative cells, taking advantage of the nuclear 
membrane reorganization events during mitosis. However, this can be particularly difficult in 
relatively quiescent tissues such as the brain, reason why transfection should be performed in 
more active cells such as NSC. 
 
Vector genome persistence is another relevant aspect that should be considered
92
. A proper 
gene therapy method must be able to express the transgene for long periods of time, which in 
certain cases means the whole lifetime of the patient. This is especially important in the case of 
plasmids, since they usually exist as episomes and are, therefore, lost upon cell division
4
. 
Nonetheless this may not represent such a relevant problem in the case of relatively quiescent 
tissues such as the brain, as mentioned before, since the cell turnover is relatively slow, 
allowing periods of gene expression that may be sufficient for therapeutic activity.  
Although the vector or gene may be sufficiently persistent, it must show sustained 
transcriptional expression. The overall level of transgene expression in the target cells tightly 
depends on the strength of the promoter (being the loss of its activity one of the main causes for 
gene silencing)
94
 and the amount of pDNA used for transfection. In non-viral gene delivery 
strategies, strong promoter/enhancers are used, such as the Cytomegalovirus (CMV) 
immediate-early promoter and SV40 early promoter
4,94
. It is still relevant to state that despite a 
vector containing a strong promoter, its activity can be attenuated in vivo
94
. 
 
Finally, a successful gene therapy approach should not trigger an immune response in the 
host
91,95
, except when DNA vaccines are being used for immunization. Specific immune 
response activating elements such as unmethylated CpG motifs are undesired, and can also 
decrease transgene expression
6,75
. This topic will be discussed in greater detail later.  
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There is not a one-fits-all approach to gene delivery in the CNS or any other kind of human 
health issues for that matter, considering the vast complexity of diseases. Rather, one must be 
able to realize the advantages of the different approaches available and refine them into their 
most suitable application. 
 
1.4.1 - Viral methods  
 
A viral vector is a modified viral particle, which takes advantage of the highly infectious capacity 
of viruses as a means to deliver genetic material of interest into mammalian cells
96
. The 
sequences needed to produce the actual viral particle are removed from the vector, so it won´t 
generate undesirable effects in the host. Through genetic engineering, transgenes can be 
expressed by heterologous plasmids, which when encapsulated by these modified viral particles 
are able to transduce the desired genetic information in target cells
96
.  
 
A variety of recombinant viral particles including adenovirus, retrovirus and lentivirus are 
available for gene delivery. Their powerful capacity for transfecting highly proliferative cells 
makes them very useful in such cases. However, they are unable to efficiently transduce mature 
cells of the CNS
4
. The biggest issue related to viral methods concerns their safety. These 
vectors can be toxic to cells, generating an immune response from the host and they have a 
limited transgene capacity in terms of the size allocated
89
, although recently, some adenovirus 
vectors have shown to be able of transferring up to 30kb of genetic material, while mediating 
long-term gene expression, without presenting immunological issues
97
. 
 
Although viral methods remain the most efficient method to deliver genes into mammalian cells, 
with around 70% of the gene therapy-related clinical trials accounting for viral methods, the 
triggering of immunological responses, along their relative toxicity and overall genetic instability 
due to random integration
91
,still remain serious issues that need further investigation in order to 
implement safer strategies. Besides, the inability to produce meaningful numbers of viral units 
through large-scale production holds back its broader use in gene therapy
68
. 
1.4.2 - Non-viral methods 
 
Virtually all macromolecules and chemicals of non-viral origin that are capable of allocating 
genetic material and delivering it into target cells can be considered non-viral vectors. 
 
Non-viral vectors usually show lower transfection efficiencies than their viral counterparts, but 
are perceived as much safer, and are more feasible in ex vivo applications
6
 reason why much 
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attention has been given to the development of non-viral strategies. A more specific targeting of 
tissues or organs can be accomplished by the superficial functionalization of non-viral particles, 
in order to interact solely with certain antigens. They usually present easier production than viral 
vectors, which makes them suitable for larger scale approaches
92
. 
 
One of the oldest methods for transfection, first described in 1973
98
 is based on precipitation 
with calcium phosphate, generating DNA-calcium phosphate complexes that are able to enter 
the cells through endocytosis. More recently, DNA has been complexed with a wide variety of 
chemicals including polymers such as polylysine, polyethylenimin, polysaccharides among 
others, although these pose some issues in the diffusion into cells and surviving endossomal 
degradation
6
. Lipossomes are spherical double-layer membranes enclosing the genetic material 
to be delivered
99
. These take advantage of its physico-chemical similarities to the cell 
membranes, being able to diffuse through them
99
. The transfection efficiencies achieved with 
this technique are relatively high, with authors reporting around approximately 74% 
mesenchymal stem cells being effectively transfected
100
. Electroporation uses an electric 
impulse capable of momentaneously disrupting the electric gradient between the two sides of 
the membrane, allowing the DNA (negatively charged as the phospholipids in the membrane) to 
freely pass through the membrane into the cell
92
. Up to 70% of transfection efficiencies have 
been achieved with this technique
101
. Microporation is a recent technology consisting of a 
modified type of electroporation, which uses a micropippete tip as a reaction chamber. A 
golden-coated electrode with a surface area of 0,33 mm
2
 is responsible for the depolarization of 
cell membrane
102
. In our laboratory, as high as 60% transfection efficiency was achieved with 
mouse neural stem cells
103
 and 40% with bone marrow-derived mesenchymal stem cells
104
. 
Some other recent technology has suggested the polyethylene glycol-polyethyleneimine (PEG-
PEI) is capable of condensing small interfering RNA (siRNA) into spherical nanoparticles, 
capable of transfecting as high as 86% of neural stem cells
105
. 
 
Plasmids 
 
Plasmids are circular or linear DNA molecules produced in bacteria. Often, the genes carried by 
plasmids confer bacteria some kind of genetic advantage, through the expression of antibiotic 
resistance markers
106
. A gene or set of genes of interest may be cloned into plasmids, and 
propagated by bacteria, in order to obtain a meaningful number of clones. 
 
Plasmid DNA finds application in a very large spectrum of gene delivery tools, being the basis 
for vaccine development. They can also be delivered directly into the target tissue or cells by 
microinjection. Some successful cases report that the process of microinjecting plasmid DNA to 
cattle zygotes did not alter their morphology, with more than 70% of the injected cells 
expressing the reporter eGFP gene
107
. Direct injection into target tissues is an approach that 
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reports some successful number as well. On the other hand, plasmids can be packaged into the 
variety of vectors previously described. 
 
There are some barriers that need to be surpassed in order to implement strong and reliable 
methods of gene delivery through plasmid vectors. Some of the issues are related to their weak 
transfection capacity of non-dividing cells; the silencing of transgene expression due to bacterial 
sequences; immunogenicity derived from unmethylated CpG motifs and insertional mutagenesis 
with potential for malign transformation and the overall toxicity of transfection agents
95
. The size 
of the molecule has also been proven a determining factor for efficient transfection. pDNA is 
greatly restricted by its size (usually no less than 2000 kDa), limiting its diffusion capacity and 
absorption by the tissue
94,108
. 
 
Unmethylated CpG dinucleotides are predominant in bacterial DNA but not in vertebrates
109
.  
These motifs trigger innate or acquired immune responses
103
. They are very important in the 
activation of plasmacytoid dendritic cells and B cells that protect the organism against a variety 
of pathogens. In fact, long and stable-expression viruses become resistant through the 
decrease in their CpG content
109
. The immunogenic response mechanism is achieved through 
the Toll-like receptor 9 (TLR9) which triggers a deregulation in redox balances of the cells, 
leading to the activation of MAPKs (Mithogen activated protein kinases) and NFkB
66,109
. The 
activation of NFkB and many other transcription factors, leads to upregulation of many cellular 
proto-oncogenes and proinflammatory cytokines. The pharmaceutical industry takes advantage 
of these unmethylated CpG motifs, in order to produce vaccines
109
. However, in gene therapy 
the opposite action is required. The elimination or drastic reduction of these motifs content from 
therapeutic plasmids must be achieved, in order to eliminate any inflammatory response from 
the host, and also to reduce transgene silencing
103
. 
 
Taking into the account the amount of vectors available, and the solid confirmation of the 
therapeutic value of cloning genes of interest into plasmids, creativity is the limiting step in the 
establishment of useful approaches that are able to surpass the abovementioned barriers. 
 
1.4.3 - Gene delivery to the Central Nervous System 
The brain´s access is highly limited due to the protection conferred by the cranium. Also, the 
blood-brain barrier (BBB) is impermeable to most of the molecules and proteins present in the 
blood stream which strongly restricts the brain´s access through the main circulatory system 
routes
83,110
.  This is the main reason why most of the gene delivery techniques to the CNS are 
based on the direct infusion of vectors into the brain´s parenchyma (the functional tissue of the 
brain)
68
. 
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Viral vectors remain the most prominent method to deliver genes into the CNS
68
. Namely, 
adeno-associated virus (AAV)-mediated transgene expression has been showed to hold a solid 
potential when applied into the brain parenchyma of Parkinson´s disease patients, showing 
considerable recovery while no relevant adverse effects were observed
111
. Still, besides some 
successful cases, viral vectors present major safety issues, reason why non-viral methods 
should be optimized for this purpose. An effective way to avoid BBB block is through PEGylated 
immunoliposomes (PILs), formulated with monoclonal antibodies that allow the crossing of the 
BBB, through the interaction with specific cell receptors
68
. Electroporation has also been used 
directly in the brain of a variety of adult animals, to deliver therapeutic plasmids, being stated as 
a safe and effective method to modify cells in the CNS, being arguably a robust method for 
treatment of Alzheimer´s and Parkinson´s diseases, as well as depression
92
. 
 
Another meaningful, relevant approach is the ex-vivo modification of cells such as NSC, HSC or 
MSC which are known to migrate to injured regions
68
. This approach is particularly interesting, 
and NSC have been shown to be great target-specific carriers of therapeutic agents to the CNS. 
NSC can be used as delivery agents, whereas the localized secretion of numerous molecules 
such as anti-tumoral drugs may provide a successful alternative to highly invasive treatments, 
with many of the approaches showing extended survival of animal subjects, and at times being 
responsible for total tumour regression
75
. For instance, ex-vivo genetically modified NSC have 
been shown to be able of delivering a cytosine deaminase to an intracranial tumor (clinical trial 
ID: NCT01172964). In the referring study, there was evidence of extensive migration of NSC, 
suggesting that even a systemic application of these cells preferentially repopulates an 
intracranial glioma
112
. Overexpressing neurotrophic factors in NSC has also been showing 
promising results from a clinical standpoint. Vascular endothelial growth factor (VEGF)-
overexpressing NSC were transplanted into a rat spinal cord injury model. The genetically 
modified cells were able to increase gliogenesis and angionesis, ameliorating the severe 
symptoms of this condition
113
. GDNF has been overepxressed in NSC, as well. These have 
resulted in a decrease of infarct, yielding overall better behavioural results while protecting 
ischemic brain in rats from apoptosis
114
.  
 
NSC hold a tremendous potential of applications, even in the adult brain. The combination of 
NSC-based therapy with other techniques may provide more specific, effective and safer 
strategies to deliver genes in the CNS. There is a wide variety of cell and gene therapy 
approaches to the CNS, considering the high amount of neurogenic and neuroprotective agents 
available and the potential of NSC. Nonetheless, one of the main hurdles in neurological tissue 
regeneration is discovering the right combination and amount of each growth and/or 
neurotrophic factor to be delivered to cells.  However, the ex-vivo modification of NSC can be of 
great value. It allows the control of gene expression, in a sense that both the timing and amount 
of transgene expression may be susceptible of control
115
. 
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2. Materials and Methods 
 
 
2.1 Bacterial strains and plasmid DNA 
 
Escherichia coli XL-Gold (Stratagene, Santa Clara, CA, USA) was the chosen bacterial strain to 
produce the desired plasmid. Bacterial cells were cultivated at 37ºC in luria-bertani (LB) medium 
(20 g/L, Sigma-Aldrich®, St. Louis, MO, USA) with orbital agitation (250 rpm). 
 
The parental plasmid MN530A-1, containing the BDNF gene (741 bp) was purchased from 
System Biosciences (SBI). The plasmid in which BDNF’s and GFP’s cloning was performed was 
the pcDNA3.1 plasmid (Invitrogen
TM
, Carlsbad, CA, USA). Throughout this work the plasmid 
containing the BDNF gene (741 bp) will be called pcDNA3.1-BDNF, and the one harboring GFP 
sequence (720 bp) will be referred to as pcDNA3.1-GFP.   
 
 
2.2 BDNF amplification by PCR 
 
BDNF gene was amplified from the parental plasmid by the polymerase chain reaction (PCR), 
using the forward primer with the sequence  5´- GGG AAG CTT ATG ACC ATC CTT TTC 3´ , 
containing a BamHI restriction site (in bold) and the reverse primer  5´- AAA GGA TCC TCA 
TCT TCC CCT TTT 3´ harboring a HindIII restriction sequence (in bold). 
The primers presented melting temperatures of 56ºC and 54ºC , and C+G contents of 46% and 
42%, respectively. A series of PCR reactions were performed, containing 10 ng of template 
DNA, 1.5 μL of each primer at a 10 μM concentration, and 25 μL of KOD Hot Start Mix 
(Novagen®, Milipore®, Darmstadt, Germany) and adding miliQ water to a 50μL total reaction 
volume. The initial PCR step consisted in heating the mixture at 95ºC for 2 min. Then, the 
second step consisted in heating the mixture at 95ºC for 20 sec. The third step occurred for 10 
sec at 51ºC for primers’ annealing. Fourth step was performed at 70ºC for 15 sec for fragment 
elongation. The steps 2 to 4 were repeated as a cycle 40 times. For the final elongation step, 
the mixture stayed at 70ºC for 10 min. When the PCR reaction ended, all the volume was 
loaded into a 1% agarose gel for BDNF bands confirmation. 
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2.3 BDNF cloning into pcDNA3.1 
 
After the right BDNF bands were confirmed, these were extracted from the gel, and the DNA 
was purified by NZYGelpure (NZYtech®, Lisbon, Portugal). This fragment was digested with 
both BamHI and HindIII as described earlier in section 2.2. The digested fragment was then 
again loaded into a 1% agarose gel and once more extracted into pure digested fragments. 
 
Both digested plasmid DNA and BDNF fragment samples were evaporated using Speed 
Vacuum (ThermoScientific
TM
, Waltham, MA, USA) for 75 min at 60ºC, at medium speed. For 
concentration assessment, 1μL of each concentrated sample was loaded into a 1% agarose gel, 
and band intensity was visually compared to the Ladder III (200-10000 bp) (NZYtech®).  
 
For plasmid cloning, a 1:1 and 3:1 ratio of insert/vector was used. 1μL of T4 DNA Ligase 
(Promega, Madison, WI, USA) was added to the mixtures, along with 1uL of T4 buffer 
(Promega), and either 1:1 ug of insert/vector or 3:1 μg of insert/vector. MiliQ water was added to 
a total 10 μL ligation reaction volume. The reaction occurred at room temperature overnight. 
The next day, competent cells were transformed as described earlier. A few colonies were 
picked and inoculated overnight in 5 mL LB containing 50 μg/mL ampicilin at 37ºC, 250 rpm. 
Purification of plasmid DNA and partial or double digestion was performed. The pcDNA3.1-GFP 
plasmid had been previously constructed. A confirmation on its correct construction was 
performed by digesting it with HindIII and ApaI restriction enzymes. The latter has a restriction 
recognition site in the sequence 5´ … GGGCCC … 3´. 
 
When correct plasmid construct were confirmed (see figure 2.3.1), transformed cell banks were 
created. For this, a single colony was grown as described previously, and the next day, a new 
culture was initiated at a OD600nm of 0.1. When OD600nm reached a value of approximately 0.8, 
800 µL of the cell suspension were loaded into cryovials containing 20% glycerol, and the 
aliquots were stored at -80ºC.
 
 
After the larger scale production, both pcDNA3.1-BDNF and pcDNA3.1-GFP were purified using 
Midiprep endotoxin free purification kit (Macherey-Nagel, Duren, Germany) following the high 
copy manufacturer’s protocol. Concentration of purified plasmids was assessed by NanoDrop 
(ThermoScientific™) bioanalyser, by measuring absorbance at 260nm. 
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A  B  
 
 
Figure 2.3.1  -  pcDNA3.1-BDNF (A) and pcDNA3.1-GFP (B) plasmid maps, containing the respective 
BDNF and GFP genes. The most important elements of the plasmid are displayed: the CMV promoter; T7 
promoter binding site; multiple cloning sites (MCS); BGH polyadenilation signals (BGH pA); SV40 promoter 
and origin; EM7 promoter; Zeocyn resistance marker; SV40 polyadenilation signal (SV40 pA) and ampicilin 
resistance marker. 
 
 
 
2.4 Transformation of bacterial strains 
 
Competent cells were transformed with the desired plasmid by the heat-shock protocol. In brief, 
5 µL of pcDNA3.1 was added to 100 µL of E.coli competent cells and incubated on ice for 30 
min. After that, the mixture was placed on a water bath at 42ºC for 45 sec to 1 min and then 
again on ice for 2 min. 900 µL of LB medium was added to the mixture and cells were incubated 
at 37ºC, 250 rpm for 1 hour. After that, cells were centrifuged at 4000 rpm for 5 min. 900 µL of 
the supernatant was discarded, and the pellet was ressuspended in the remaining 100 µL. The 
cellular suspension was afterwards spread on solid LB media with zeocyn (50 µg/mL) and 
incubated at 37ºC at 250 rpm overnight. Positive colonies were inoculated in 5 mL of LB media 
with zeocyn (50 µg/mL) and incubated at 37ºC with shaking at 250 rpm overnight. For large 
scale production of plasmids, selected colonies were grown as described, and when the desired 
OD600nm was reached, adequate volume of the cellular suspension was inoculated on 400 mL 
total volume of LB medium, and incubated 37ºC, 250 rpm, overnight.  Plasmids were purified by 
the DNA purification kit NZYMiniprep (NZYtech®). When the correct plasmid production was 
assessed by agarose gel electrophoresis, they were digested with BamHI and HindIII 
(Promega) restriction enzymes. For this, 10 μL of plasmid DNA is digested in 2 μL of Buffer E 
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(Promega) with 0.5 μL of each enzyme, and adding sterile water to the mix to a 20 μL total 
working volume and incubated at 37ºC for 1 hour. The whole sample was then loaded into an 
agarose gel, and then the correct bands were dissected from the gel and purified by 
NZYGelpure kit (NZYtech®). 
 
 
2.5 Neural Stem Cell culture 
 
2.5.1 Cell lines 
 
Two cell lines were used throughout this work: the CGR8-NS cell line, derived from the mouse 
embryonic stem cell line CGR8 in the laboratory of Professor Austin Smith, Welcome Trust 
Centre for Stem Cell Research, Cambridge, United Kingdom; and the ReNcell VM (Millipore®) 
(herein abbreviated to “ReN” cells), an immortalized human neural progenitor cell line with the 
ability to readily differentiate into neurons and glial cells. “VM” stands for ventral 
mesencephalon, region of the brain from which the cells were isolated
116
. 
 
2.5.2 Expansion of Neural Stem Cells 
 
The cells were thawed either from liquid nitrogen or -80ºC stock, containing cells ressuspended 
in 900 µL of Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) – 
GlutaMAXTM medium (Life Technologies™, Carlsbad, USA) and 100 μL of dimethyl sulfoxide 
(DMSO (Sigma®, St. Louis, USA)). The frozen vials were thawed by submerging the mixture in 
a 37ºC water bath, and by resuspending in DMEM/F12. The mixture was centrifuged for 3 min 
at 1000 rpm, and the supernatant was discarded in order to remove DMSO from the mixture. 
The appropriate medium was then added to the cells. CGR8-NS cells were ressuspended in 
DMEM/F12 supplemented with 10 ng/mL EGF and FGF2-2 (Peprotech, London, UK), 1% N-2 
and 1 μl/mL  B27® supplement (both from Life Technologies™), 20 g/mL insulin (Sigma®) and 
1% penicillin/streptomycin (Life Technologies
TM
). The described medium composition will be 
herein termed expansion medium for this cell line. 
ReN cells were ressuspended in DMEM/F12 supplemented with 20 ng/mL EGF, 10 ng/mL 
FGF2-2 (Peprotech), 1% N-2 and 20 μl/mL  B27® supplement, 20 g/mL insulin and 1% 
penicillin/streptomycin. This will be shortened to expansion medium for this cell line throughout 
the text. 
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Trypan blue dye exclusion test (Gibco®, Invitrogen
TM
) was used to determine cell viability by 
counting cells in a hemocytometer under an optical microscope. Viability was described by 
equation (1): 
 
              
  
      
                                                                     
 
where VC is the viable cell number and NVC the non-viable cell number. 
 
An appropriate number of cells were then platted into either T-flasks, or tissue culture plates 
(Falcon®, BD Biosciences, San Jose, CA) under adherent conditions and incubated at 37ºC 
and 5% CO2-humidified atmosphere.  
CGR8-NS cells were expanded on untreated surfaces, although after transfection assays, 
fibronectin-coated surfaces were used. This was achieved by diluting the appropriate amount of 
fibronectin (3 μg of fibronectin/cm
2 
surface area) in sterile phosphate buffered saline (PBS, 
Gibco®, Invitrogen
TM
) and loading a sufficient amount of the solution to cover the culture plate 
surface. The plate was subsequently incubated at room temperature for 1 hour and the mixture 
was aspirated, just before cell inoculation. 
 
ReN cells were expanded on polyornithine and laminin-coated surfaces. Coating with 
polyornithine/laminin was performed by pre-coating the desired surface with polyornithine 
(diluted in PBS) and incubating the mixture at 37ºC for at least 30 min. Then this solution was 
aspirated and a mixture containing the appropriate amount of laminin (10 μg of laminin/cm
2 
surface area) was loaded to the surface and the mixture was incubated at 37ºC for at least 4h. 
 
When cells reached sub-confluency they were harvested using Stempro® Accutase® (Life 
Technologies
TM
) by incubation at 37ºC and 5% CO2-humidified atmosphere for 3-5 min. 
Afterwards, the cell suspension was diluted 1:1 with DMEM/F12 and centrifuged at 1000 rpm for 
3 min. The pellet was ressuspended in an appropriate volume of culture medium, and cell 
viability was assessed by trypan blue dye exclusion method, as described before in this section. 
 
2.5.3 Differentiation of Neural Stem Cells 
 
For differentiation purposes, only ReN cells were used throughout this work. For this, ReN cells 
were plated on polyortnithine/laminin-coated 24-well plates (Falcon®, BD Biosciences) at a 
density of 75,000 cells/cm
2
. A 1:1 mixture of DMEM/F12 medium (Gibco®, Invitrogen
TM
) and 
Neurobasal® Medium (1X) without Phenol Red (Gibco®, Invitrogen
TM
) was used, along with 20 
μl/mL B27® supplement (Gibco®, Invitrogen
TM
), being incubated at 37ºC and 5% CO2-
humidified atmosphere. This will be described further in the text as the differentiation medium. 
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For positive control on BDNF effect on cell culture, 50 ng/mL of BDNF (Gibco®, Invitrogen
TM
) 
was added to the mixture on selected cells. Culture conditions were maintained as described 
until differentiation was achieved. Differentiation was carried out for 12 days, adding fresh 
medium every 3 days. 
 
 
2.6 Neural Stem Cell transfection 
 
Neural stem cells were transfected using one of three different methods: an electro-physical 
method called microporation, and two chemical techniques - cationic polymer and lipid-based 
transfection reagents. 
 
2.6.1 Microporation 
 
CGR8-NS and ReN cells (150,000 – 200,000 CGR8-NS cells for each transfection) were 
resuspended in 10 L of a resuspension buffer (RB), provided by the equipment manufacturer 
(Life Technologies™), and incubated with the adequate amount of plasmid DNA.  The 
transfection reaction was carried out by the Microporator MP100 (Digital Bio/(Neon), Life 
Technologies
TM
). After microporation, the mixture was plated into 24-well plates containing 
adequate pre-warmed culture medium without antibiotics, and incubated at 37ºC and 5% CO2-
humidified atmosphere for 24 hours. After this, fresh medium containing antibiotics was added. 
Cells could be visualized under the fluorescence optical microscope Leica DMI 3000B (Leica 
Microsystems GMbH, Heerbrugg, Switzerland), where GFP transfected cells could be easily 
identified using the appropriate fluorescence filter, allowing for recognition of efficiently 
transfected cells. Cells were then harvested at specific times for the different assays performed. 
Cell viability (equation 1), and cell recovery was assessed for microporated samples (equation 
2): 
 
Recovery (%) = 
  
   
                                                   (2) 
 
 
where VCc is the total viable cell number in the control (non-transfected cells). For quantitative 
assessment of transfection efficiency, Fluorescence Activated Cell Sorting (FACS) was 
performed, as will be described later. 
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2.6.2 Cationic polymer-based transfection 
 
CGR8 cells were transfected with TurboFect (TF) (ThermoScientific™) at 150,000 – 200,000 
cells per reaction. The process involved complexation of a polymer-based reagent complexed 
with pcDNA3.1-GFP, either through the standard protocol or through reverse transfection. The 
first is achieved by the addition of a 2:1 TF:DNA ratio to cells expanded for 24 hours in 
expansion medium, and incubated at 37ºC and 5% CO2-humidified atmosphere on fibronectin-
coated dishes for 5 hours, time after which, fresh media is added, and cells are allowed to grow 
for 24 hours. 
In reverse transfection, the 2:1 TF:DNA ratio mix is added to the bottom of 2 cm
2
 surface area 
wells. 200,000 cells in suspension are then added on top of the mixture, and incubated at 37ºC 
and 5% CO2-humidified atmosphere on fibronectin-coated dishes. From this point, the cells 
receive the same treatment as mentioned above. Assessment of viability, recovery and 
percentage of GFP-expressing cells was performed as described earlier in section 2.6.1. 
 
2.6.3 Lipid-based transfection 
 
CGR8 and ReN cells (150,000 – 200,000 cells for each transfection) were transfected with 
Lipofectamine® 2000 (LF, Invitrogen™). The reaction involved complexation of the lipid-based 
reagent either with pcDNA3.1-GFP or pcDNA3.1-BDNF.  After optimization of the protocol, a 2:1 
LF/DNA ratio was chosen for the next experiments. Lipoplex formation was carried out by 
diluting the appropriate amount of LF in Opti-MEM® (Gibco®, Invitrogen™) medium, and mixing 
by vigorous vortex agitation for 15 sec. In parallel, the adequate amount of plasmid DNA was 
diluted in Opti-MEM® (Gibco®, Invitrogen™) medium, and mixed by pipetting up and down. The 
cationic-lipid was then mixed with plasmid DNA. The solution was mixed by pipetting up and 
down, and incubated for at least 20 min, at room temperature. Finally, the lipoplexes were 
added to cells expanded for 24 hours in appropriate expansion medium without antibiotics, and 
incubated at 37ºC and 5% CO2-humidified atmosphere on differently coated dishes depending 
on the cells used, for 5 hours. After that, fresh media containing 1% penicillin/streptomycin 
(Gibco®, Invitrogen
TM
) was added, and cells were allowed to grow for 24 hours. Assessment of 
viability, recovery and percentage of GFP-expressing cells was performed as described earlier 
in section 2.6.1. 
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2.7 Flow cytometry 
 
GFP-transfected cells were harvested and counted. Cell viability and recovery were assessed 
as described previously in section 2.6.1. Cells were centrifuged at 1000 rpm for 5 min, and the 
pellet was ressuspended in 500 µL of a 2% paraformaldehyde (PFA) solution for cell fixation 
and the mixture was transferred to FACS tubes. The percentage of GFP
+
 cells was then 
measured in the BD FACScalibur™ equipment (BD Biosciences). The results were analyzed 
with CellQuest software (BD Biosciences). Statistically significant results are considered when a 
minimum of 1000-gated cells are counted. Between one and three replicates were used for 
each assay. 
 
2.8 Immunocytochemistry  
 
For immunofluorescence analysis of cells, complete culture medium was removed from cells, 
and 4% PFA was added for 10 min at room temperature for cell fixation. The cells were then 
washed with PBS (Gibco®, Invitrogen
TM
) and incubated for 1 hour with blocking solution (10% 
normal goat serum (NGS, Gibco®, Invitrogen™) and 0.1% Triton X-100 (Sigma-Aldrich®) in 
PBS). Afterwards, blocking solution was removed and cells were incubated with adequate 
primary antibody diluted in a staining solution (5% NGS and 0.1% Triton X-100 in PBS) 
overnight at 4ºC. The primary antibodies used were neuronal Class III β-Tubulin (TuJ1) 
(Covance, dilution 1:2000), Nestin (1:200, R&D Systems®), GFAP(1:200, Milipore). The next 
day, after washing with PBS, the cells were incubated with the appropriate secondary 
antibodies for 1 hour at room temperature. After this step, cells were once more washed with 
PBS and incubated with DAPI solution (Sigma-Aldrich®) (15:10000 in PBS) for 5 min at room 
temperature. Two final washes with PBS were performed, and the cells were ready for analysis 
under a fluorescence optical microscope - Leica DMI 3000B (Leica Microsystems GMbH). 
Photographs of the culture were taken with a Nikon® digital camera DXM1200F (Nikon, Tokyo, 
Japan). 
 
2.9 Alamar blue assay 
 
Alamar blue assay is based on a fluorometric/colorimetric cell growth indicator that is produced 
according to the detection of metabolic activity from a certain cell culture. This indicator is the 
dye resazurin, which is by itself weakly fluorescent. It is then reduced to the resorufin form, a 
highly red fluorescent compound, by means of proliferative activity within a given culture or by 
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other test-agents added to the medium
117
. It is a widely used method to assess the proliferation 
of a large spectrum of cell lines, and the cytotoxicity of agents within various chemical classes. 
 
Briefly, selected cell populations were exposed to a certain test-agent, that will be highlighted 
later. After that, alamar blue was diluted 1:20 in differentiation medium, and cells were 
incubated with the agent for 1 hour. Then, fluorescence measurements were taken at pre-
determined time-points (in this work 1 hour, 3 hours and 24 hours after the exposure to the test-
agent), using the Plate Reader Tecan Infinite M200 Pro (Tecan®, Männedorf, Switzerland), by 
monitoring fluorescence excitation at 560nm and emission at 590nm. Absolute fluorescence 
intensity is returned by the equipment. Most of the time, relative fluorescence intensities are 
preferred since the purpose of the assay is to compare populations exposed to different test-
agents. So, the relative fluorescence intensity was calculated according to equation 3: 
 
                                       
                                 
                                 
          (3) 
 
 
In order to test glutamate toxicity in a differentiated neuronal cell culture, ReN cells maintained 
in differentiation medium for 12 days were exposed to 100 µM, 500 µM, 2 mM and 4 mM of 
Glutamate (Sigma-Aldrich®) for 2 hours. Adequate volume of a 100 mM glutamate stock 
solution was added to the differentiation medium and then added to cells. Following the 2 hours 
of incubation, 3-day old differentiation medium was added to the cells. Glutamate toxicity was 
then assessed by the Alamar blue assay, at 1 hour, 3 hours and 24 hours after glutamate 
exposure. 
 
To evaluate the potential protective activity from BDNF, the cells were exposed to 4 mM of 
glutamate for 2 hours. After that, 3-day old conditioned medium containing BDNF secreted by 
transfected cells was added to glutamate-exposed cells. 
 
2.10 Qualitative analysis of neuronal neurites by ImageJ® 
software 
 
Non-transfected ReN cells were differentiated using either the standard protocol, or by adding 
50ng/mL of exogenous BDNF (Life Technologies™) to the medium, for positive-control on 
BDNF. Transfected ReN cells with BDNF were differentiated using the standard protocol. Fresh 
differentiation medium was added every 3 days. Differentiation was induced for 12 days. At the 
end of the process, the cells were fixed for immunostaining as described on section 2.8. Tuj1-
stained cells were analyzed with ImageJ software. The plugin NeuronJ is a semi-quantitative 
method that allows the measurement of neurites of neurons as depicted on figure 2.10. Neurites 
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are herein understood as the processes that emerge from the soma (nucleus), which include 
axons and dendrites. First, the background fluorescence is subtracted with a rolling ball radius 
of 50 pixels. Then a color threshold is defined in order to enhance the contrast between neurites 
and other particles. The image is then binarized, rendering positively stained particles the 
maximum intensity (shown in dark) against zero intensity particles (in white). Through the 
NeuronJ plugin, tracings are created by placing the cursor at one end of the cell, stretching the 
tracing which is automatically calculated by the software, until the other end of the cell. The 
tracings are then automatically measured. From this, primary neurites and secondary neurites 
can be identified. The former are the neurites emerging directly from the soma. Secondary 
neurites emerge from primary neurites. 
 
 
 
 
 
Figure 2.10 - Sequence of operations performed on ImageJ® until a final binarized image is achieved, 
following neurite measurement of NeuronJ plugin. 
 
2.11 Quantification of mRNA extracts by real time PCR 
 
In order to estimate the expression of specific gene transcripts, cells exposed to different 
conditions were plated into 6-well plates, then being harvested at specific times and the pellet 
was kept at -80ºC. Later, total mRNA extracts were isolated using High Pure RNA Isolation kit 
(Roche®), according to the manufacturer´s protocol. Then, mRNA was converted to cDNA 
using the Trancriptor First Strand cDNA Synthesis kit (Roche®). For this, 1µg of mRNA was 
combined with anchored-oligo(dT)18 primers (final concentration 2.5 μM) and PCR-grade water 
until a volume of 13μL was reached. Then, Reverse Transcriptase Incubation Buffer was added, 
as well as Protector RNAse Inhibitor (final quantity of 20 units), deoxynucleotide mix (final 
concentration of 1mM of each) and Transcriptor Reverse Transcriptase (final quantity of 10 
units), to a final volume of 20μL. cDNA was obtained by heating the mixture at 55ºC for 30min, 
followed by reverse transcriptase inactivation by heating the mixture to 85ºC for 5min. After 
obtaining cDNA, RT-PCR was performed, using several primers for the analysis of different 
genes including Nestin, Sox2, GFAP, β3-tubulin, IL-6, BDNF, Caspase7 and the housekeeping 
gene GAPDH (StabVida®, Portugal) (table I). The RT-PCR was performed using the 
manufacturer´s protocol (LightCycler®FastStart DNA Master SYBR Green I, version 18) from 
Roche®. Briefly, a set of 20µL solutions were prepared, which included 4mM MgCl2, 2µL of 
template cDNA and a primer mix (final concentration was 0.5µM for each), filling the remaining 
volume with PCR-grade water. The control solutions contained 2µL of PCR-grade water 
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replacing cDNA. The reactions were performed using the equipment StepOnePlus™ (Life 
Technologies™). Between one and two replicates were used in the different assays. 
 
Gene expression was assessed through the 2-
CT
 method described elsewhere
118
, in which 
expression of each gene is displayed related to the control, assuming that both target and 
reference genes are amplified with a near 100% efficiency (equation 4). 
 
                                                                                                             (4) 
 
Two RT-PCR programs were run depending on the samples. Program 1: pre-incubation step at  
95ºC for 10 min; denaturation step at 95ºC for 30 sec; annealing at 58ºC for 30 sec; elongation 
step at 72ºC for 30 sec. The last three cycles were repeated 40 times. Program 2: all steps were 
run at the same temperature for the same amount of time. The last three cycles were repeated 
35 times.  
 
For obtaining the melting curve, the temperature was increased to 95ºC for 15 min, then being 
decreased to 60ºC for 1 min, and then again increased to 95ºC through 0.2ºC increments, and 
remaining for 15 min at this last temperature. 
 
Table I - Primers used in mRNA quantification by real-time PCR. 
Gene Primers 5´ -> 3´ (fwd/rev) 
Tm 
(ºC) 
Number of 
bases 
Amplicon 
size (bp) 
GAPDH 
ACGACCCCTTCATTGACCTCAACT / 
ATATTTCTCGTGGTTCACACCCAT 
60.2 / 
56.4 
24 / 24 324 
Sox2 
GTATCAAGGAGTTGTCAAGGCAGAG / 
TCCTAGTTCTTAAAGAGGCAGCAAAC 
57.1 / 
56.7 
24 / 25 78 
Nestin 
GCCCTGACCACTCCAGTTTA / 
GGAGTCCTGGATTTCCTTCC 
56.8 / 
54.9 
20 / 20 200 
GFAP 
CTGTTGCCAGAGATGGAGGTT / 
GGAGAACAACCCTCTGAGCTG 
57.5 / 
56.4 
21 / 21 289 
β3-tubulin 
CCATCTTGCTGCCGACAC / 
CAATAAGACAGAGACAGGAG 
56.7 / 
49.6 
18 / 20 126 
IL-6 ATGAACTCCTTCTCCACAAGC / 
GTTTTCTGCCAGTGCCTCTTTG 
21 / 
22 
21 / 22 264 
BDNF 
CATCCGAGGACAAGGTGGCTTG /  
GCCGAACTTTCTGGTCCTCATC  
60.2 / 
57.9 
22 / 20 161 
Caspase7 
AAGAGCAGGGGGTTGAGGAT / 
TGAAGAGGGACGGTACAAACG 
58.4 / 
56.8 
20 / 21 84 
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2.12 Statistical analysis 
 
When appropriate, the Mann-Whitney-U test was used to evaluate the significance of the 
difference between two groups of independent samples that did not show a normal distribution 
and/or homogeneity of variances. Significant analyses (p <0.05) are displayed as * on selected 
data. 
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3. Results & Discussion 
 
3.1 - Amplification of BDNF by PCR 
 
In order to construct the desired plasmids (see section 2.1), the BDNF gene was amplified by 
PCR as described in section 2.3. Figure 3.1 shows a unique band with less than 800bp (BDNF 
gene is 741bp long - sequence in appendix), confirming that the gene was efficiently amplified, 
without rendering non-specific amplification products. 
 
 
Figure 3.1 - Confirmation of efficient BDNF gene (741bp) amplification by PCR on a 1% agarose gel. LIII 
is the DNA Ladder III (NZYtech®). 
 
 
3.2 - Cloning of BDNF into pcDNA3.1 
 
The BDNF gene was extracted from the gel and cloned into the plasmid pcDNA3.1 (see section 
2.3). In order to confirm the correct construction of the plasmid, a restriction analysis of the 
construct was performed (Figure 3.2.1). In parallel, another restriction analysis was performed in 
order to confirm the correct construction of the previously produced pcDNA3.1-GFP. 
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Figure 3.2.1 - Confirmation of the correct plasmid constructions on a 1% agarose gel. The samples are 
presented in their non-digested form (ND); single digestion with BamHI (BI) and HindIII (HI) and double 
digested with the pair BamHI/HindIII (BI/HIII) and HindIII/ApaI (HI/AI) for pcDNA3.1-BDNF and pcDNA3.1-
GFP, respectively. LIII corresponds to the DNA ladder III (NZYtech®). 
 
Supercoiled DNA migrates better through the agarose gel due its more compact structure, 
appearing further from the loading point in the gel, as it can been seen for both non-digested 
samples (ND) in Figure 3.2.1. A single cut in the double strand DNA leads to its linearization, 
which has a lower mobility than supercoiled DNA, reason why the single-digested bands appear 
slightly closer to the beginning of the gel (pcDNA3.1-BDNF restricted by BamHI (BI) and 
pcDNA3.1-GFP by HindIII). A double digestion by the enzymes previously used to achieve the 
construct, allows for the detection of the cloned gene. As it can be seen in Figure 3.2.1, double 
digestion of pcDNA3.1-BDNF by BamHI and HindIII results in two bands, one with 
approximately 5000bp corresponding to the linearized plasmid without the gene of interest, and 
another slightly shorter than 800bp, corresponding to the BDNF gene which is 760bp long. The 
same can be reasoned for pcDNA3.1-GFP, with the GFP gene band showing up below the 
800bp reference band (GFP gene is 720 bp long). 
 
The constructs were then produced in a larger scale, and purified by endotoxin-free purification 
kits (see section 2.4). The properties of the plasmids obtained are summarized in Table II. 
 
Table II - Concentration of plasmids obtained after purification with the Endotoxin-free NucleoBond® Xtra 
Midi EF kit, and purity assessment through ratios of absorbance at different wavelengths. Concentration 
and purity of plasmid DNA is presented as the mean value ± SD of three independent measurements. 
 Concentration (μg/μL) A260/A280 A260/A230 
pcDNA3.1-GFP 1.20 ± 0.01 1.88 ± 0.01 2.44 ± 0.17 
pcDNA3.1-BDNF 1.11 ± 0.03 1.85 ± 0.01 2.41 ± 0.42 
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Based on the information shown in Table II, the plasmid DNA presented very low contamination 
with proteins, since a A260/A280 ratio of 1.8 is usually related to pure DNA
119
. The ratio A260/A230 is 
used to evaluate eventual contamination of DNA with compounds such as phenol and guanidine 
commonly used in DNA extraction kits. This value should be between 2.0 and 2.2
119
. Slightly 
higher values were obtained, meaning that the sample if virtually free of such contamination.  
 
3.3 - Transfection of mouse Neural Stem Cells 
 
The purified plasmids were then ready to use on neural stem cells. The following results refer to 
the transfection of the mouse ES-derived NSC line CGR8-NS. 
 
3.3.1. Microporation 
 
Microporation is a novel type of electroporation, which carries out the transfection reaction in a 
10μL chamber, taking advantage of a 0,33mm
2
 electrode surface
102
. Recently, mouse NSC 
were successfully microporated with plasmid DNA, with 75% of the transfected cells expressing 
a transgene
103
. 
 
CGR8 cells were first microporated using previously optimized conditions - 1 pulse of 1500V for 
20ms (2 x 10
5
 cells/microporation), and then plated on untreated surfaces. This resulted in cell 
death of all the population, not allowing for further analysis (data not shown).  Surface coating 
with extracellular matrix components has been shown to provide a better support for cell 
attachment and to promote overall cell survival. Hence, the appropriate culture wells were 
coated with CELLStart™ (Gibco®, Invitrogen corporation, Carlsbad, CA), and microporation 
was carried out in the conditions stated before, using 0.5µg of pcDNA3.1-GFP.  Cells survived 
in these conditions, allowing for continuous analysis of the cell culture for 4 days (figure 3.3.1). 
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Figure 3.3.1 - CGR8-NS cells microporated using 1 pulse of 1500V for 20ms, and 0.5μg of pcDNA3.1-
GFP. Cell viability for transfected and control cells (A), and cell recovery of transfected cells (B). Values 
were calculated based on mean ± SD of 4 to 6 countings of 2 replicates. 
 
 
Coating with CELLStart™ seems to have made a difference in cell survival. This is a xeno-free 
substrate, widely used in the attachment of hNSC, hMSC and hESC
120
. The transfection 
process reduced cell viability in approximately 20% compared to the non-microporated control. 
Cell viability values quickly stabilized and are similar in both conditions for the remaining days. 
Cell recovery, on the other hand, is very low, never reaching more than 25%, which suggests 
that these conditions may still be very harsh for cells. Cell recovery is lower on the 2
nd
 day than 
the day post-transfection. It is important to highlight that this is a value that represents the 
percentage of viable cells on a culture, in comparison to the percentage of viable cells on a 
control, reason why it is not directly related to the values of cell recovery on other days. This 
means the culture had a lower proliferative activity on that day, which could be related to their 
higher needs for nutrients while on a recovery state. One way to evaluate this would be provide 
fresh medium to the culture on the day after transfection. 
 
In order to evaluate the effect of BDNF on cell recovery, CGR8 cells were microporated with 
pcDNA3.1-GFP and pcDNA3.1-BDNF, using 1 pulse of 1500V for 20ms, and 0.5µg of plasmid 
DNA. Days 2 and 4 were analyzed (figure 3.3.2) 
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Figure 3.3.2 - CGR8-NS cells microporated using 1 pulse of 1500V for 20ms, and 0.5μg of pcDNA3.1-
GFP or pcDNA3.1-BDNF. Cell viability of transfected and control cells (A) and cell recovery of control cells 
(B) on days 2 and 4. Values were calculated based on the mean ± SD  of 4 to 6 cell countings of 2 
replicates. 
 
The transfection with a BDNF-containing plasmid did not improve cell recovery since no major 
differences were observed. Debilitated cells by the microporation process may be not so 
responsive to such signaling in a destabilizing environment. Higher values of cell recovery on 
the first few days post-transfection may be particularly important to address these questions, in 
order to draw conclusions on a healthy culture. These results may suggest that the transfection 
was performed under sub-optimal conditions. The parameters used were previously optimized 
for much smaller plasmids (as little as 2.2kb, as compared to 5.7kb in this work)
103
. The size of 
plasmids is an important factor that interferes with the efficiency of the transfection process. In 
fact, a reduction in plasmid size is directly related to an increased transfection efficiency of stem 
cells
108,121
. Unfortunately, in these assays, it was not possible to harvest enough number of cells 
to evaluate the transfection efficiency by flow cytometry. 
  
 
3.3.2. Cationic polymer-based transfection 
 
Cationic polymers are widely used transfection agents for gene delivery (forming polymer-DNA 
complexes usually called polyplexes
122
). Their versatility arises from the possibility to synthesize 
polymers with the desired properties, allowing for tunning of its length, geometry, ramification 
and functionalization
122
 among other parameters. 
 
CGR8 cells were transfected with the commercial cationic polymer-based reagent TurboFect 
(ThermoScientific®), complexed with pcDNA3.1-GFP.  
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Fig. 3.3.3 - CGR8 cells transfected with TurboFect, using a 2:1 TF:DNA ratio (μL/μg) for each reaction. 
Cell viability, recovery and transfection efficiency is presented for each protocol performed. Cell viability 
and recovery were calculated based on the mean value ± SD of 2 cell coutings from 3 replicates. 
Percentage of GFP+ cells is the mean value ± SD of 3 replicates. 
 
TurboFect (TF) is a polymer-based transfection reagent. Both normal and reverse transfection 
protocol yielded negligible percentage of transfected cells - around 3% and 2%, respectively. 
This can be explained by the use of polyplexes with incorrect TF/DNA ratio. An incorrect ratio 
can lead to the formation of an overall negatively charged complex, which is incapable of 
efficiently interacting with negatively charged cell membranes, and therefore incapable of 
penetrating cells. 
 
Cell viability is virtually the same for both transfection protocols and for the non-transfected 
control cells. This may be corroborated by the fact that such a low number of cells were 
successfully transfected, so the overall process did not affect most of the cells in culture. On the 
other hand, only around 10% of cells recovered from reverse transfection. In this approach, the 
TF/DNA mixture is placed on the bottom of the cell culture wells (see section 2.6.2), and the 
cellular suspension is then added to the mixture. Hypothesizing the formed complexes present 
an overall negative charge, the deposition of these particles in the bottom of the well may have 
resulted in electrostatic repulsions that prevented cells from reaching the fibronectin coating. 
This would lead to a critical decrease in cell adhesion causing extensive cell death. Overall 
polyplex charge is one of the parameters that highly influences the interaction with living 
cells
91,94
. A more detailed and time consuming optimization of this transfection protocol would 
be required , in order to evaluate the best TF/DNA ratio to use within NSC. However, as the 
goal of this work was not the optimization of novel transfection reagents we decided to proceed 
using a well-established method with higher number of cell lines, and both somatic and stem 
cells tested. 
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3.3.3. Lipofection 
 
Lipofection is throughout this work referred to as the transfection process through the lipid-
based reagent Lipofectamine® 2000 (Invitrogen™). This reagent has been complexed with 
either the pcDNA3.1-GFP or pcDNA3.1-BDNF plasmids, forming lipoplexes.  
 
 
3.3.3 a. Assessment of the optimal LF/DNA ratio 
 
As in cationic polymer-based transfections, also in lipid-based reactions the overall charge of 
the lipoplex is important. In order to assess which Lipofectamine® 2000/DNA ratio (herein 
termed LF/DNA) provides the best transfection efficiency of CGR8 cells, four different ratios 
were tested - 1, 2, 2.5 and 3 (μL of LF/μg of DNA) (figure 3.3.4). 
 
 
A  B  
 
Fig 3.3.4 - CGR8-NS cells transfected with Lipofectamine® 2000 under different LF/DNA ratios. Cell 
viability is shown for each ratio and for LF quantities alone (A). Cell recovery and transfection efficiency 
(B). Cell viability and recovery were calculated based on the mean ± SD of 3 independent cell countings 
from 2 replicates each. Percentage of GFP
+
 cells is the value of one experiment.  
 
 
A decrease in total cell number (data not shown) and viability was observed with an increasing 
LF/DNA ratio, although with very slight differences between different ratios, achieving a cell 
viability of ~80%. A control test with no pDNA was performed in order to evaluate possible 
harmful effects from LF alone in cell viability. All LF quantities rendered more than 70% cell 
viability, which means that the transfection reagent per se, does not present significant toxicity 
to cells. This is in agreement with other reports, stating that LF provided less than 20% toxicity 
in MSC
123
, which is considered suitable for most applications
124
. 
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Figure 3.3.5 - Fluorescence images of CGR8 cells transfected with lipoplexes of several LF/DNA ratios. 
Brighfield images can be seen on the left. GFP-expressing cells can be seen (in green) on the right side of 
the panel. 
 
A good balance between both molecules charges must be achieved in order to get the best 
electrostatic interactions between complexes and cell surfaces
99
. Ratios of 2, 2.5 and 3 
provided the higher percentage of GFP-expressing cells, around 8%, 11% and 8% respectively. 
Nonetheless, a LF/DNA ratio of 2 was chosen for the upcoming assays, for resulting in more 
than 80% of cell recovery, contrasting with the 60% of the other ratios mentioned, while showing 
similar percentage of GFP expressing cells.  
 
 
3.4. Transfection of human neural progenitor cells 
 
Considering the low transfection efficiency achieved with mouse ES-derived NSC, the human 
ReN cell VM line was chosen for the remaining experiments. 
 
3.4.1. Microporation 
 
In order to optimize the microporation protocol for this type of cells, ReN cells were 
microporated with 0.5μg of pcDNA3.1-GFP (2x10
5
 cells/microporation) using several different 
conditions varying the number of pulses, length of the pulse(s) and voltage. The cells from each 
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condition were then plated on laminin-coated wells of a 24-well plate. The results are displayed 
on figure 3.4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.1 - ReN cells microporated using 0.5µg of pcDNA3.1-GFP under several conditions. Cell 
viability and recovery are calculated based on the mean ± SD of 3 cell countings from 2 replicates. 
Percentage of GFP
+
 are the value of one experiment for each condition. The conditions are characterized 
by the voltage (V), length of pulse(s) (ms) and number of pulses (p). 
 
 
Beyond the displayed settings, an additional condition was performed using 1 pulse of 1500V 
for 30ms which resulted in extensive cell death of the culture, not allowing for further analysis. 
Cell viability seems to increase when lower voltages are used, which may be due to the harmful 
effect of the electrical discharge during the process. In fact, microporation has exhibited 
cytotoxicity in human adipose tissue-derived stem cells, directly related to increase in voltage 
and pulse number
125
. Cell recovery is very low in all the conditions, with the best condition 
yielding only 40% of recovered cells, which may indicate that the microporation process may 
need further optimization. This value was obtained using what it seems to be the milder 
condition of all (1 pulse of 900V for 30ms). Comparing this condition with 2 pulses of 900 V for 
15ms, it is possible to observe that the latter presents lower cell recovery, while the overall 
voltage is the same, which again may support the fact that the microporation process itself is 
detrimental to these cells.  
 
Special attention must be given to the quantity of GFP
+
 cells. Only using 1 pulse of 900V for 
30ms or 2 pulses of 900V for 15ms, it was possible to obtain sufficient gated-cells to perform a 
statistically significative analysis (approximately 2800 and 2200 gated-cells were obtained, 
respectively). While this is below the recommended values (minimum of 10000 gated-cells), it 
suggests a tendency, in which the first condition may provide the best overall results. The 
remaining conditions resulted in less than one thousand gated-cells, not allowing for further 
analysis. 
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3.4.2. Lipofection 
 
3.4.2 a. Transfection of ReN cells with GFP and BDNF-gene carrying plasmids 
 
Considering that the chosen LF/DNA ratio of 2 was the most efficient condition on CGR8 cells 
lipofection, the same was attempted on ReN cells. In order to evaluate the validity of the 
assumption, ReN cells were plated at 75.000 cells/cm
2 
on laminin-coated wells, and transfected 
the next day with a 2:1 LF/DNA ratio. Cells were harvested either one or three days after the 
transfection (figure 3.4.2).  
 
A  B  
C  D  
 
Fig 3.4.2 - ReN cells transfected with Lipofectamine® 2000 complexed with either pcDNA3.1-GFP or 
pcDNA3.1-BDNF (2μL/1μg). Cell viability, recovery and percentage of GFP
+
 cells for day 1 (A) and day 3 
(C). Fluorescence images of transfected ReN cells, by day 1 (B) and day 3 (D).  Values are presented as 
the mean of 4 to 6 independent coutings from 2 replicates ± SD. Percentage of GFP+ cells is presented as 
the mean of 2 replicates ± SD. 
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On day 1, transfected cells present cell viabilities around 70% which is relatively lower than the 
90% achieved with control cells, although these represent sufficiently high values that allow 
further studies with these cultures.  On the other hand, cell recovery is very low, which may be 
caused by the high percentage of transfected cells (~35%). By the third day, cell viability was 
evened out in both transfected and control cells (approximately 80%). Cells transfected with 
BDNF gene-containing plasmid seem to have recovered significantly better than GFP reporter-
gene containing plasmids. BDNF is known for its pro-survival and proliferative effects on neural 
stem cells
62
, which may be the cause for this increase in cell recovery, although more data 
would be required in order to confirm this result, since the opposite was observed on CGR8 
cells (see 3.3.3), which greatly prevents any solid conclusion to be drawn from the specific 
impact of BDNF on cell recovery. Moreover, the fact that the human BDNF gene is being used 
on mouse derived NSC might have affected his biological expression and function despite the 
differences in only 11 amino acids (corresponding to a 95.6% homology according to 
sequences available at ncbi.nlm.nih.gov). 
 
Around 35% of the population expresses GFP on the first day. A relatively low amount of 
literature reporting the lipofection of neural stem cells does not allow for a more solid 
comparison on transfection efficiencies. Nonetheless, the results obtained report slightly higher 
values than the ones reported on other occasions. Falk and colleagues achieved around 4% of 
GFP
+
 cells with LF
126
, while around 20% transgene-expressing adult rat hippocampal cells were 
reported by Tinsley et al
89
. Plasmids exist within cells as episomes and are, therefore, lost upon 
division, leading to a decrease in GFP-expressing cells, consisting in 15% of the total cell 
population by day 3.  
 
A wide variety of new sophisticated commercial formulations are available nowadays, and 
several other transfection reagents have been used on NSC. Tinsley et al tested 6 different 
reagents, where FuGene and ExGen500 rendered 11% and 16% transgene-expressing adult 
hippocampal progenitors.  The later is a commercial cationic polymer while the former is a non-
lipossomal transfection reagent. Cationic polymers are relatively easily manipulated, being 
flexible in its structure
122
, allowing for protonation of the molecules making it easier to interact 
with other macromolecules such as nucleic acids. Non-liposomal reagents, may they be lipids or 
polymers, present an alternative to liposomes. They are capable of forming micelles or droplets, 
containing lipophilic surfaces that interact with cell membranes, forming an encapsulated 
complex that encloses the genetic material to be delivered. Electroporation has also been 
widely used on NSC. Richard et al, were able to successfully transfect 70% neural precursor 
cells
101
. In this method, the application of an electrical current momentaneously disrupts the 
charge gradient across the membrane. While there is not a consensus about the actual 
mechanism through which DNA enters the cell (either through pore or non-pore formation), the 
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relatively higher efficiency of this method may be due to the fact that it is relatively independent 
on the stage of the cell cycle.  
 
However, viral methods still remain the most effective transfection agents. This is logically highly 
dependent on the type of virus. Retroviruses have provided a landmark in viral gene therapy 
when in 1990, hematopoietic stem cells were retrovirally transduced in vitro, in order to provide 
a fundamental enzyme, usually lacking in cases of X-linked severe combined immunodeficiency 
(SCID-X1)
127
. Re-infusion of modified HSC into patients suffering from the disease provided full 
and sustained correction of the enzyme function. However, retroviruses are incapable of 
infecting non-replicating cells. Still, they have been used on adult NSC, achieving around 60% 
of transfection efficiency. Lentivirus is a type of retrovirus, which has been exploited for its ability 
to infect non-mitotic cells, offering long-term expression of the transgene with relatively low 
toxicity
4
. NSC have been transduced with lentiviral vectors, preserving differentiation potential 
and proliferation in vitro, as well as their migratory capacity with the CNS
77
. Adenoviruses are 
non-enveloped icosahedral particles capable of infecting both dividing and non-dividing cells
4
. 
Adenovirus-mediated transfection has achieved up to 68% efficiently modified mouse NSC in 
vitro
126
. 
 
3.4.2 b. Assessment of differentiation potential after transfection 
 
Neural stem cells have the ability to migrate to certain regions in the brain when transplanted, 
being able to express transgenes
128
. It is important to evaluate the differentiation capacity of 
transgene-expressing NSC, which would be the basis of a NSC-based therapy taking 
advantage of these cells as gene vehicles capable of expressing genes coding for clinically 
meaningful molecules. In order to evaluate the capacity of transfected cells to differentiate into 
either neurons or glial cells, ReN cells were lipofected as described before (section 2.6.3) and 
plated at 75000 cells/cm
2 
on laminin-coated wells. Differentiation was induced on the next day, 
following the manufacturer´s protocol, which consists in culturing cells in a 1:1 mix of 
DMEM/F12 and Neurobasal® Medium, supplemented with B27, without any growth factors. 
Differentiation was carried out for 12 days, adding fresh medium every 3 days. The results are 
summarized on figure 3.4.3: 
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Figure 3.4.3 - ReN cells transfected with Lipofectamine® 2000. One day after transfection, differentiation 
of the culture was induced. Cell viability, recovery and percentage of GFP+ cells on day 1 (A) and day 12 
(B) of differentiation.  Dot-plots of flow cytometry analysis of ReN cells transfected with GFP, acquired on 
day 1 and 12 of differentiation, using a wide gate (C). Histograms based on the previously presented dot-
plots (D). Cell viability and recovery was calculated based on the mean value ± SD of 3 independent 
countings from 3 replicates each. GFP+ cells is presented as the mean ± SD of 2 replicates. 
 
 
One day after transfection, around 35% of cells express GFP which is consistent with the 
previous results (see figure 3.4.2a). By the 12
th
 day of differentiation, a shift in the population 
morphology occurs (figure 3.4.3c). The x-axis is represented by the forward-scattered light 
(FCS), which is directly related to cell size, while the y-axis represents the side-scattered light 
(SSC), directly related to cell granularity or internal complexity
129
. Comparing the overall sizes 
and granularity of the populations along the differentiation process, it is possible to observe a 
shift into a population presumably consisting of differentiated cells, which present a decreased 
size as observed on the microscope, as well as cell debris and other particles of reduced size 
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and complexity, such as organelles. By the 12
th 
day, considering the gate showed in figure 
3.4.3c, approximately 23% of the cell population is expressing GFP. However, the real value of 
GFP expression is probably masked by the presence of cell debris showing autofluorescence. 
Since there is strong evidence that, during the process of differentiation cells appear to show a 
reduced size, a wide gate was considered in this case, in order to include both differentiated 
and differentiating cells (see figure 3.4.3c). By the 12
th
 day, the more evident peak on the 
histograms (identified by the red arrow) (figure 3.4.3d) probably corresponds to what was 
initially considered cell debris, and at this point, by differentiated cells as well. However, 
plasmids are known to be diluted away in the culture upon division, and considering the 
previous results, where only 15% of cells were expressing the transgene at day 3, it is expected 
that by the 12
th
 day of culture, a negligible number of cells still expresses GFP. For this reason, 
another analysis of the data was performed using a smaller gate, comprising the population 
regarding presumably the initial neural stem cell population at the first day of culture (figure 
3.4.4): 
 
 
A  B  
C  
D  
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Figure 3.4.4 - ReN cells transfected with Lipofectamine® 2000. One day after transfection, differentiation 
of the culture was induced. Cell viability, recovery and percentage of GFP+ cells on day 1 (A) and day 12 
(B) of differentiation.  Dot-plots of flow cytometry analysis of ReN cells transfected with GFP, acquired on 
day 1 and 12 of differentiation, using a small gate (C). Histograms based on the previously presented dot-
plots (D). Cell viability and recovery was calculated based on the mean value ± SD of 3 independent 
countings from 3 replicates each. GFP+ cells is presented as the mean ± SD of 2 replicates. 
 
 
On the day post-transfection, around 35% of the population is expressing GFP, according to this 
analysis, which is in agreement with the previous analysis (see figure 3.4.2). The use of a 
smaller gate does not change the value of GFP-expressing cells on day 1, since the 
composition of the gated population (3.4.4c) is virtually the same as the one considered before, 
taking into account not enough time has passed for the generation of differentiated cells. 
However, at the end of the differentiation protocol, not enough cells are gated, preventing a 
statistically significant analysis (less than 1000 gated cells). 
 
The smaller gate is neglecting important data, excluding differentiated cells from the analysis at 
the end of the differentiation protocol, while the wider gate is including too many events, most of 
which probably regard autofluorescent cell debris. It is believed the real number of GFP-
expressing cells may lie between the two analyses, showed on figures 3.4.3c and 3.4.4c. To 
confirm this, staining of dead cells with propidium iodide could be carried out in order to 
distinguish viable GFP-expressing cells from non-viable cells and debris, elucidating about the 
actual composition of the population highlighted by the red arrow (figure 3.4.3d). 
 
In a parallel assay, ReN cells were plated at 75000 cells/cm
2 
on laminin-coated wells, and 
differentiated for 4 days. Afterwards, the cells were lipofected as described before, in order to 
evaluate the potential of differentiating cells to take up complexes of cationic lipids and DNA 
(figure 3.4.5). 
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Figure 3.4.5 - ReN cells within 4
th
 of differentiation were transfected with Lipofectamine 2000. Cell viability, 
recovery and GFP+ cells (A). Cell viability and recovery was calculated based on the mean value ± SD of 
3 independent countings from 3 replicates each. GFP+ cells is presented as the mean ± SD of 2 
replicates. Fluorescence microscopy picture of differentiating transfected cells (B).  Dot-plots of flow 
cytometry analysis of differentiating ReN cells transfected with GFP, acquired  day 4 of differentiation, 
using a wide gate (C). Histograms based on the previously presented dot-plots (D). 
 
It is known that exogenous transgene expression steadily decreases for 1-2 weeks
130
. In order 
to attempt a still active and stronger gene expression at the end of the differentiation process, 
ReN cells were transfected during the differentiation induction. Fluorescence microscopy 
images showed GFP-expressing cells possessing long neurites (figure 3.4.5b), typical of 
neuronal committed cells, as opposed to a smaller star-like morphology observed on non-
differentiated cells, which hints at the differentiation ability of these cells. Around 13% of the 
population was able to take up the plasmid and express the transgene, according to flow 
cytometry results. Nevertheless, this value may as well be masked by the presence of auto-
fluorescent cell debris as described before. Performing the analysis with the smaller gate yields 
only about 3% of GFP-expressing cells (figure 3.4.6). Once more, the real value may lie 
between those two. 
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Figure 3.4.6 - ReN cells within 4
th
 of differentiation were transfected with Lipofectamine 2000. Cell viability, 
recovery and GFP+ cells (A). Cell viability and recovery was calculated based on the mean value ± SD of 
3 independent countings from 3 replicates each. GFP+ cells is presented as the mean ± SD of 2 
replicates. Fluorescence microscopy picture of differentiating transfected cells (B).  Dot-plots of flow 
cytometry analysis of differentiating ReN cells transfected with GFP, acquired  day 4 of differentiation, 
using a small gate (C). Histograms based on the previously presented dot-plots (D). 
 
While the actual mechanism of lipoplex-mediated transfection is not entirely understood, some 
authors support that besides the well accepted theory of lipoplex fusion with cells membranes, 
this might occur during membrane reorganization events that undergo during mitosis. In this 
stage, the cellular membrane is highly fragile, and so the freshly released DNA from the 
endosomes has a more direct access to the nuclei of newly formed cells
131
. During 
differentiation, proliferative events are highly restricted, preventing macromolecules such as 
lipoplexes to penetrate cells
131
, and in fact, lipid-based transfection usually shows poor 
efficiency in post-mitotic neurons
132
, which could explain these results. Although these cells 
have not reached their final stage of differentiation, the majoritiy of the population is probably in 
a post-mitotic phase, preventing the lipoplexes from reaching their destination. Neurons should, 
nonetheless, be able to take up lipoplexes through fusion with the cell membrane, even though 
they are post-mitotic. However, this seems not to occur naturally. This is presumably due to 
their high sensitiveness to changes in culture conditions such as pH, osmotic pressure and 
temperature
132
. Also, the nature of their in vivo environment is highly restrictive in the uptake of 
exogenous molecules as a protective mechanism against external aggressions. Neurons may, 
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in this way, present themselves cell membranes that engage poorly in interactions with external 
molecules, especially with the size of lipoplexes. This may be the reason why the most effective 
transfection techniques on neurons so far, have been more invasive methods such as 
nucleofection, electroporation and biolistic gene transfer
132,133
. 
 
3.5. BDNF effect on the differentiation of ReN cells 
 
Non-transfected ReN cells were cultured during several passages using the conditions 
described in the section 2.5.2. In parallel, some non-transfected and transfected ReN cells (with 
LF/pcDNA3.1-BDNF lipoplexes) were subjected to differentiation. A positive control for BDNF 
effect on the process was created by adding 50 ng/mL of exogenous BDNF to selected cultures. 
Immunostaining analysis of the cultures was performed as described in section 2.8. The neural 
stem/progenitor marker Nestin was used to evaluate the multipotency of the culture. Astrocytic 
marker GFAP and neuronal marker Tuj1 were also used to detect the presence of these cell 
linages. The nuclear counter-stain DAPI was used as well to identify nuclei (Figures 3.5.1 and 
3.5.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.1 - Immunostaining of non-differentiated ReN cells. Neuronal cell marker Tuj1 and neural 
stem/progenitor cells marker Nestin are shown in red. The nuclear counter-stain DAPI in blue. Merged 
images are shown at the right. Scale bar is 50μm. 
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Figure 3.5.2 - Immunostaining of ReN cells transfected with BDNF and differentiated under standard 
conditions (A-D, M-O); non-transfected ReN cells differentiated with supplemented exogenous BDNF (E-H) 
and non-transfected ReN cells differentiated under standard conditions (I-L, P-R). The markers Tuj1 and 
Nestin are shown in red, GFAP in green and the nuclear counter-stain DAPI in blue. Scale bar is 50μm. 
 
 
 
Tuj1 is an antibody against the neuron-specific class III β-tubulin marker. It is present in all 
differentiation conditions, while being absent in non-differentiated cells (Figure 3.5.1) indicating 
that whichever method was used, neuronal phenotype cells were developed. While this marker 
does not allow for identification of the specific neuron type produced, the manufacturer´s 
protocol suggests ReN cells are readily able to differentiate into dopaminergic neurons
116
. One 
way to address this would be to use antibodies against specific proteins present in this class of 
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neurons, such as the transcription factor Nurr1, a receptor involved in the development, 
maturation and survival of DA neurons
134
. GFAP is mainly expressed in astrocytes. It is not 
possible to observe any kind of positive staining of this marker, although on some occasions, 
green staining could be observed (data not shown). This does not mean that differentiation into 
astrocytes was not achieved. It probably suggests that the immunostaining protocol used for 
astrocytes was not optimal, not allowing for drawing of any solid conclusions. Nestin is a neural 
progenitor cell marker, that is widely expressed both in transfected and non-transfected cells, 
showing a similar profile to the expression of this marker on non-differentiated cells, suggesting 
once more that the differentiation efficiency was very low, as the vast majority of the population 
still presents multipotency at the end of differentiation. Still, the lipofection process seems not to 
interfere with the differentiation process, rendering similar immunostaining profiles as the other 
conditions, rendering Tuj1-positive neurons. 
 
 
3.6. Qualitative analysis of neurites by ImageJ® software 
 
BDNF promotes neurite outgrowth and number of neurons, which has been proven on several 
occasions
84,86
. To evaluate this, a library of fluorescence microscopy pictures were analyzed 
using ImageJ® software, and through the plugin NeuronJ, total neurite and respective lengths 
were measured in each condition (see 2.10): transfected cells with BDNF; cells exposed to 
exogenous BDNF; control cells. The results are summarized on figure 3.6.1. 
 
A  B 
 
    
Figure 3.6.1 - Differentiated ReN cells cultured in either normal differentiation conditions (control), with 
supplemented BDNF (exo-BDNF) or transfected ReN cells with BDNF (pcDNA-BDNF) were 
immunostained against neuronal-marker Tuj1. Fluorescence microscopy images were analyzed and mean 
length of primary neurites (A) and  secondary neurites (B) were measured in each condition.  Results are 
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displayed as the mean ± SD of 19 independent measurements (n=19). Statistical differences are indicated 
with * for p < 0.05. 
 
Transfected cells seemed to have rendered slightly longer neurites than control cells (215μm vs 
160μm, respectively), but shorter than those exposed to the exogenous factor (215μm vs 251μm 
respectively). It is important to keep in mind that the differentiation process requires the addition 
of fresh medium every 3 days, which in the case of exo-BDNF samples means that those cells 
were exposed to a fresh dose of this factor every 3 days. On the other hand, transfected cells 
were only provided with fresh differentiation medium without any other exogenous factors, 
which means the outcome observed was derived solely on the BDNF secreted by these cells 
throughout the entire lifetime of the culture. While it is not possible to know for sure what caused 
a slight decrease in neurite outgrowth from transfected cells in relation to exo-BDNF exposed 
cells, one can hypothesize that (1) either the amount of BDNF released by transfected cells was 
not high enough to provide a more evident increase in neurite outgrowth, or (2) a depletion of 
the factor has occurred due to its uptake by the cells or by loss of function of the neurotrophin 
due to the high amount of time it has been present in culture, considering the first 2 days 
represent the peak of expression of the transgene. 
On the other hand, transfected cells seem to have rendered longer secondary neurites than 
either control or exo-BDNF cells. This suggests that BDNF may promote ramification of cells, 
which could translate in the generation of more connections with the surrounding cells, creating 
more communication routes within the neuronal network. One possible explanation to the 
generation of longer secondary neurites in transfected cells when compared to exogenous 
BDNF-exposed cells could be related to a more localized effect of the neurotrophin. BDNF is 
known to present both autocrine and paracrine signaling
135
. When the exogenous factor is 
added, widespread mixing of the medium allows all the cells in the culture to have access to the 
neurotrophin. In the transfection process, the presence of the factor in the medium results only 
from its secretion by transfected cells. In this case, immediate neighbor cells may benefit from 
the release of this neurotrophin through paracrine signalling, as well as the transfected cells 
themselves through autocrine signaling, leaving further localized cells unaltered by the lack of 
access to the neurotrophin. This may have altered the transcriptome of the positively affected 
cells, leading to the formation of more and longer secondary neurites. 
 
Therefore, these results suggest that BDNF, in fact, promotes neuronal outgrowth, and that 
even transient expression of this factor enhances the total neurite (both primary and secondary) 
length, compared to non-treated cells, being the differences significant and noted as early as 12 
days in culture. 
 
This is especially relevant since many neurological disorders results in neuronal impairment and 
severe alterations in cell morphology. Neural stem cells, able to release stable amounts of 
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neurotrophins such as BDNF, could promote the survival of damaged cells and enhance neurite 
outgrowth, leading to functional recovery of those cells. 
 
3.7. Glutamate toxicity evaluation by the Alamar blue assay 
Glutamate is the main neurotransmitter in the CNS. Nevertheless, when present in high 
concentrations, it is toxic to neurons
73
, and has been shown to reduce cell viability in neuronal 
cultures
136
. In order to evaluate glutamate toxicity, ReN cells were exposed to three solutions of 
different glutamate concentrations, and then, cell viability was assessed by the alamar blue 
assay (Figure 3.7.1). A concentration of 4mM glutamate was chosen for the next experiment. 
ReN cells within 12 days of differentiation induction were exposed to 4mM of glutamate for 2 
hours. After that, the glutamate-containing medium was replaced with conditioned medium and 
the cells were incubated for 24h in normal conditions. Conditioned medium is herein termed as 
3-day old differentiation medium containing BDNF secreted from transfected cells (with 
LF/pcDNA3.1-BDNF) and supplemented with fresh B27® supplement. In these assays, the 
respective test-mediums were diluted 1:1 with fresh differentiation medium, after 3h. 
 
A 
 
B  
Figure 3.7.1 - Relative fluorescence intensity at different time-points of differentiated ReN cell cultures 
exposed to different glutamate concentrations (A), and to 4mM glutamate and 3-day old conditioned 
medium (B). Values are the mean ± SD of 2 replicates. 
 
At 3h and 24h after glutamate exposure, cell viability seems to decrease in a concentration 
dependent manner, with higher glutamate concentrations affecting more negatively the 
population, which hints at the presence of glutamate-induced neuronal death. At 24h there is an 
increase in the fluorescence intensity of all cultures which may be explained by the fact that the 
3-day old medium was diluted 1:1 with fresh differentiation medium, which provided fresh 
nutrients to the culture, improving its cellular activity. 
ReN cells were then exposed to 4mM of glutamate for 2 h. After that, cells were incubated with 
conditioned media. The control was subjected to 3 day-old medium from non-transfected cells. 
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A 10% increase in fluorescence intensity from BDNF-conditioned media-exposed cells is 
observed in the first 3 hours. After 24h, the fluorescence intensity is similar to the control. The 
amount of BDNF present in the medium may have not been sufficient to provide a longer 
protection from the eventual glutamate-induced neurotoxicity. Also, the concentration of 
glutamate used may have been too high for BDNF to exert a relevant action. Nonetheless, the 
increase in fluorescence intensity from conditioned medium-exposed cells occurred in all three 
time-points, which suggests consistency in the data, which ultimately may indicate that the 
existing BDNF in the medium has protected the cells, especially neurons, from the harmful 
effects of this concentration of glutamate. To our best knowledge, this is the first time that it is 
provided evidence on the effect of BDNF on a human NSC culture after glutamate exposure.  
 
 
3.8. mRNA quantification by RT-PCR 
 
ReN cells were lipofected with BDNF as described earlier and harvested on the next day (“day 
1”). One day post-transfection, differentiation was induced on other cultures, and two days after 
that (3 days post-transfection) these cells were harvested (“day 3”). The expression of six genes 
were evaluated by RT-PCR: BDNF, IL-6, GFAP, β3-tubulin, Nestin and Sox2. The results are 
displayed below and the fold increase was calculated in relation to the expression of the 
housekeeping gene GAPDH (figure 3.8.1): 
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Figure 3.8.1 - Relative fold-increase in gene expression of several genes in BDNF-transfected cells 
(compared to non-transfected cells), on days 1 and 3. Results are displayed for cell markers Nestin, 
GFAP, β3-tubulin and Sox2 on day 1 (A) and day 3 (B), for BDNF (C) and IL-6 (D). Values are the mean 
relative gene expression normalized with respect to endogenous GAPDH. Duplicates were run on ♦ 
 marked samples. 
 
From figure 3.8.2 multiple amplification products for βIII-tubulin are observed, reason why the 
relative value of gene expression this gene is masked by other non-specific amplification 
products, so the conclusions drawn from this must be carefully taken. In order to minimize the 
occurrence of non-specific products of RT-PCR, the protocol was modified (program 2, see 
section 2.11), and by day 3 all genes presented a unique band, with the fragments appearing 
with the correct length. 
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Figure 3.8.2 - RT-PCR reaction products on days 1 (A) and 3 (B). The DNA ladders used were the 500bp 
ladder (Lonza®) and the HyperLadder 50bp (Bioline®), respectively. 
 
Both neural stem/progenitor and differentiated cell markers are down-regulated in transfected 
cells (figure 3.8.1). One day after transfection, cells are still in a recovering state, and are 
maintained in proliferative conditions, reason why Nestin and Sox2 should be extensively 
expressed. One day post-transfection, cells were exposed to differentiation conditions. Neural 
stem/progenitor cell markers should be then down-regulated, and an increase in lineage-
specific markers should be detected. The opposite seem to have occurred though. Neuronal 
progenitors have been shown to proliferate for several days after withdrawal of both EGF and 
FGF-2 mithogens
137
. This was related to the possible existence of a latent period through which 
cells must undergo before they actually exit the cell cycle and initiate the molecular mechanisms 
that lead to a committed-fate
137
, which could account for the low levels of Nestin and Sox2 
expression. 
 
Meanwhile, BDNF shows a 1,5 x 10
5
 fold-increase in its expression by day 1. This confirms the 
successful expression of the transgene on transfected cells. Such a high value of gene 
expression can be explained by the regulation of its activity by the strong CMV promoter. This 
promoter has been widely used on neural cell types, enhancing strong transcription of the 
transgene
4,94
. By day 3, the correct value of BDNF expression could not be evaluated since the 
difference in the Ct values returned differed on 5 units (23.18 and 18.85) which would strongly 
undermine the validity of the outcome. The selection of only one of the values would mean that 
either its expression was increased to 3x10
5 
 fold or decreased to 7x10
4
 fold, when compared to 
day 1. Although it is not possible to draw any conclusions from this, it is known that the 
transgene expression starts to decay with time
92
. In particular, transgenes under the control of 
the CMV promoter, as used in this work, have their peak of expression 1 to 2 days after 
administration, and then steadily decay during 1 to 2 weeks
130
, reason why this value should in 
theory, be lower than one day post-transfection. The vector used is a regular plasmid containing 
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unmethylated CpG motifs, which are known to trigger immune responses in the host, through 
the activation of the TLR9 receptor
95,138
. This potentially led to the increased expression of the 
pro-inflammatory cytokine IL6, whose expression is potentiated by the presence of the referred 
motifs
139
. While also the correct value of expression of this cytokine is not known at day 1 (since 
the Ct values returned differed on 5 units), by day 3 around a 300 fold-increase in its expression 
compared to non-transfected cells is observed.  The degradation of the plasmid and its overall 
dilution due to proliferation
92
 may suggest that by the first day post-transfection, its expression 
should be highly increased. In fact, using one of the Ct values results in a fold-increase IL-6 
expression of approximately 5746. For a more accurate assessment of the actual value of gene 
expression, the experiments returning significantly different Ct values should be repeated. 
 
Glutamate shows neurotoxicity, mediated by the induction of a calcium influx via NMDA (N-
methyl-D-aspartate) receptors. This triggers an appropriate response that comes along with 
glutamate-induced neuronal death
136
. In order to provide some insight about the effect of 
glutamate and BDNF on a differentiated ReN cell culture, differentiation was induced on ReN 
cells for 12 days. By the end of the differentiation protocol, long neuronal processes extended 
throughout the entire culture. A 2 hour-long exposure to 4mM of glutamate was performed by 
adding the appropriate amount of glutamate to the differentiation medium. After that, fresh B27® 
supplement was added to 3-day old differentiation medium and the mixture was added to the 
cells (herein termed “Glu” samples) for 24 hours. To test the effect of BDNF on glutamate-
induced neurotoxicity, after the exposure to glutamate, cells were incubated with 3-day old 
conditioned medium supplement with fresh B27®. This conditioned medium contains BDNF 
secreted by lipofected cultures with pcDNA3.1-BDNF.  
 
The expression of three genes were evaluated - caspase7, a gene activated upon cell death 
and an inducer of apoptosis; BDNF and β3-tubulin. The results are displayed on figure 3.8.3: 
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Figure 3.8.3 - Relative fold-increase in gene expression of several genes in glutamate-exposed cells (Glu) 
and cells incubated with conditioned-media after glutamate exposure (Glu+BDNF) (compared to non-
exposed  control cells), at the 12
th
 day of differentiation. Results are displayed for Caspase7 (A), BDNF (B) 
and β3-tubulin (C). Values are the mean relative gene expression normalized with respect to endogenous 
GAPDH. Duplicates were run on ♦ marked samples. 
 
 
 
Figure 3.8.4 - Agarose gel of the RT-PCR reaction products. The DNA ladder used was the HyperLadder 
50 bp (Bioline®). 
 
 
This exposure to glutamate led to a major fold-increase in caspase7 activity (~40 fold), 
confirming extensive apoptotic cell death. On the other hand, cells that were later incubated in 
BDNF secreted by transfected cells seem to have been spared from the harmful effects of 
glutamate, reducing the expression of this pro-apoptotic protein to near-control levels. There is 
extensive evidence of the protective activity of BDNF from glutamate-induced neurotoxicity in 
cortical neurons
140,141
. However, the mentioned studies have only addressed this question when 
cells are pre-treated with the neurotrophin. Here, some evidence indicates that even after the 
aggression has occurred, BDNF can actually rescue or revert this toxicity in some way. 
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The mechanism of glutamate-induced neurotoxicity has been proposed to occur through the 
activation of the NMDA receptor by glutamate, which leads to a calcium influx into neurons, 
which in turn leads to formation of free radicals triggering neurotoxicity
141
. BDNF is known to 
promote calcium homeostasis, through the activation of genes that regulate calcium and free 
radicals metabolism
141,142
 as well as increasing the expression of the anti-apoptotic protein Bcl-
2
143
. So, glutamate-induced neurotoxicity may actually occur, even in the presence of BDNF, 
although, this neurotrophin may be able to protect neurons from further aggression by the 
activation of those protective genes within 24 h. On the other hand, BDNF also regulates the 
degree of phosphorylation and expression of the NMDA receptor units
144
, which is in theory, a 
quicker way to prevent calcium-influx due to NMDA activation by glutamate, which would 
explain the difference in the results observed within only 24 h. 
 
The BDNF gene is itself up-regulated when cells are exposed to glutamate alone. Despite the 
real value of gene expression being masked by non-specific products of amplification (figure 
3.8.4), BDNF seems to have been, to some degree, up-regulated in this situation. One 
explanation resides in the fact that glutamate, being the main excitatory neurotransmitter in the 
CNS, is ultimately closely related to the direct release of neurotrophins. In fact, BDNF and 
glutamate are closely inter-related and co-regulate one another. During pre-synaptic activity, 
BDNF enhances the release of glutamate, while the latter increase the transcription and 
secretion of the neurotrophin
144
. A direct relationship between glutamate exposure and 
consequent BDNF release has been reported
145
. Its expression decreases when conditioned-
medium is added to cells. Possible explanations include (1) the assumption that BDNF indeed 
prevented glutamate-induced toxicity, and in this sense, this agent did not trigger the release of 
higher amounts of the neurotrophin, although still enhancing its expression in some degree, or 
(2) BDNF, enhancing the release of glutamate, which in turn promotes the expression and 
secretion of the neurotrophin, partially regulates its own expression on a indirect way. These 
explanations are not mutually exclusive and may have taken place simultaneously.  
 
The exposure to a BDNF-containing medium increases β3-tubulin expression (~70 fold), which 
confirms that neuronal differentiation is promoted by this neurotrophin, which has been proven 
on several occasions
84,86,143
. As stated before, the differentiation efficiency was very low 
throughout this work. The addition of BDNF to the differentiation medium might help to improve 
its efficiency and in effect, may induce neuronal commitment.  
 
This experiment pretended to simulate an inflammatory environment that is common in 
neurological disorders such as ischemic brain injury
146
, ALS
147
 and AD
148
, where high 
concentrations of glutamate have been reported. In AD, damaged cells release high amounts of 
glutamate as they die, which overstimulates surrounding healthy cells, leading to a 
phenomenon called excitotoxicity. This eventually leads to widespread cell damage
148
. Neural 
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stem cells have been proven efficient vehicles of genes, with homing capacity and correct 
migration in vivo
35
. The results presented here may suggest that not only transfected cells with 
BDNF would benefit from its highly protective properties, but also other cells within that micro-
environment, which could be rescued from glutamate-induced neurotoxicity, even preventing 
healthy cells from this aggression. BDNF alongside many other neurotrophins such as NGF and 
NT-3 have had their highly beneficial effects proven
142
. However, the delivery of the functional 
proteins in an attempt to treat neurological disorders is greatly prevented by the BBB
83,149
. Ex-
vivo modification of neural stem cells to overexpress neurotrophins and other molecules of 
proven therapeutical interest could be a promising alternative.  
 
Besides gene silencing and plasmid degradation, which have been suggested to occur in this 
work, the lifespan of transplanted cells is also an important factor to keep in mind. These can 
range from 1 week for intestinal epithelial cells to lifelong established nerve cells
94
, such as 
CNS cells. In this sense, even though considering the abovementioned barriers to gene 
therapy, the high amount of transgene expression that has been shown to occur hints that this 
approach could be helpful in the recovery of milder cases of neurological disorders that are 
caused by the knockdown of fundamental genes or loss of function of specific proteins.  
 
It is important to highlight that glutamate is the major excitatory neurotransmitter in the CNS, 
and BDNF, being able to modulate its activity into a positive outcome through the cooperative 
interactions described, it might also provoke undesired responses such as blocking important 
synaptic pathways. Therefore, one should be careful in the analysis of these results, and in its 
hypothetic translation into clinical solutions. In gene therapy, for regenerative medicine 
applications lower and more stable levels of transgene expression are preferred. In this sense, 
a range of concentration/levels of expression of this neurotrophin should be determined, within 
which its activity would result in a desired outcome. 
 
A fair comparison between the three transfection methods used throughout this work is not 
possible since not all of them were efficiently optimized. Lipofection was the only method whose 
conditions have been used on both mouse and human neural stem cells, providing significantly 
different percentages of GFP-expressing cells - 8% and 35%, respectively. The typical doubling 
time of these cells were investigated, in order to provide some insight about the differences in 
the results emerging from those two cell lines. ReN cells have an estimated doubling time of 20-
30h
116
, while CGR8 have around 14 hours
150
. This presumably suggests that the main route of 
entry of liposomes into cells was not through membrane reorganization events during mitosis. 
CGR8 cells, presenting higher proliferation rates, should in theory, present higher transfection 
efficiencies. Liposomes also bind with cell surfaces through electrostatic interactions. These are 
dependent on the surface components of cell membranes, such as cell matrix components, 
phospholipids and glycoproteins
92
. In order to better understand why ReN cells seem to be 
more prone to lipid-based transfection than CGR8 cells, the composition of the cell membranes 
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of these cell lines should be an interesting parameter to take into account. On the other hand, 
upon internalization, lipoplexes must release the DNA, and the remaining journey of the plasmid 
may be quite different in both cell lines. In this sense, cellular uptake may not be the limiting 
step in the whole process, and it may show similar kinetic profiles on both cell lines. Upon 
lipoplex destabilization, DNA must diffuse through the cytoplasm, avoiding degradation, reach 
the nuclear membrane, where it must be transported into the nucleus and finally the 
transcriptional machinery must be activated for the transgene to be expressed
99,122
. However, 
live tracking of lipid-DNA complexes would be required for a correct judgement on the actual 
mechanism of transfection, which is beyond the scope of this work.  
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4. Conclusion and future trends 
 
Neural stem cells have a tremendous potential as the object of study of neurological disorders, 
through the establishment of neurological disease models. They can be used from a 
developmental biology of stem cells standpoint, and in regenerative medicine through gene and 
cell therapy, either as delivery agents of therapeutic molecules and/or for cell replacement. The 
use of NSC as therapeutic molecule delivery agents has raised hope for the treatment of certain 
neurological disorders, considering their capacity to stably express transgenes
89
, and their 
homing capacity into the adult brain
151
. Viral vectors remain the most efficient transfection 
method for stem cells, and in particular, lentivirus in the case of neural stem cells
151
, being most 
of the clinical investigation based on them. However, serious safety concerns arise from viral-
vectors, namely due to immune responses triggered by the host against viral particles and 
insertional mutagenesis
138
. 
 
 
Non-viral vectors may be an alternative in gene delivery, showing increased safety, with low 
tumorogenic potential
93
 however presenting a decreased efficiency when compared to their viral 
counter-parts. A successful non-viral gene delivery-based therapy should aim at overcoming the 
limiting steps of this approach. Clearly understanding the mechanisms of vector uptake by the 
cells would lead to higher transfection efficiencies. Non-virally transfected neural stem cells 
have also been showing promising results. GDNF-overexpressing neural stem cells were 
transduced through calcium phosphate technique. These cells integrated into the host striatum, 
expressing the transgene for at least 4 months, resulting in protection of dopaminergic neurons 
from degeneration
152
. The in vivo administration of therapeutic molecules faces major issues 
such as non-specific targeting, loss of function through protein destabilization and decreased 
bioavailability as a result of poor interaction with the desired cells or tissues. Ex-vivo 
modification of cells, on the other hand, gives researchers a greater control of the system, 
allowing for the manipulation of the desired cells only. Furthermore, the timing and amount of 
transgene expression may be susceptible of tight control through the use of adequate 
systems
115
. 
 
The aim of this work was the overexpression of the brain-derived neurotrophic factor in neural 
stem cells, through non-viral gene delivery strategies. Human neural stem cells were 
successfully microporated (~20% GFP-expressing cells), while maintaining 70% cell viability. 
On the other hand, both mouse and human neural stem cells were effectively transfected with 
Lipofectamine® 2000 (8% and 35% GFP-expressing cells, respectively), while maintaining 70-
80% cell viability, which constitute promising results in comparison to the available literature. 
Furthermore, transfected cells were able to differentiate properly, while however, the efficiency 
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of the differentiation remained relatively poor. BDNF-transfected human neural stem cells were 
able to provide neurons with longer primary and secondary neurites, while also promoting 
neuron ramification, when compared to non-transfected cells.  
 
Neurotoxicity was induced in a differentiated human neural stem cell culture by the addition of 
glutamate. A slight, but consistent decrease in cellular activity was caused by the exposure to 
this agent. Secreted BDNF from transfected cells was able to prevent a decrease in cellular 
activity upon glutamate exposure for the first 3 hours. mRNA quantification by real-time PCR 
allowed for the observations that secreted BDNF was indeed, able to reduce drastically 
apoptotic cell death events on glutamate-exposed cells, as well as promoting neuronal 
differentiation through the up-regulation of neuronal cell-marker Tuj1. 
 
Interesting experiments to be performed would include the exposure of transfected cells to 
glutamate. This would provide insight about the behavior of these cells faced with glutamate-
induced toxicity, in comparison to non-transfected cells exposed to the neurotrophic factor upon 
the aggression. The evaluation of the paracrine effect of BDNF could be performed through 
NSC culture on plastic inserts containing permeable membranes. This would allow non-
transfected cells to co-exist in the same environment (i.e, media) as transfected cells, while not 
directly interacting with each other. Finally, important measurements would include protein 
quantity assessment in the media. This could be performed through ELISA kits using a specific 
antibody against the human-BDNF protein, or through western blotting. 
 
The conversion of neural stem cell potential into an effective cell-therapy reality must overcome 
fundamental issues. For one, the determination of the signaling pathways and the major 
molecules in the process that regulate proliferation, differentiation and migration of these cells is 
of the utmost importance. In order for the transplanted cells to reproduce known differentiation 
profiles and kinetics in vivo, the adequate chemical cues behind this mechanism should be 
known. Another problem relates to the immune rejection upon transplant. Overcoming this issue 
would require autologous transplants to be a viable option. However, the isolation of NSC from 
the adult brain and achieving meaningful cell numbers through in vitro culture still remains 
challenging. In addition to that, the use of genetically engineered stem cells is still in its infancy, 
mainly due to concerns about their safety. 
 
Regardless of the abovementioned imposed problems, there is no doubt that a tremendous 
progression in the mechanisms of neural developmental biology have been made. A quite vast 
repertoire of evidence has provided meaningful insight into the nature of NSC as clinically 
valuable products for cell and gene therapy, resulting in very promising outcomes in a wide 
variety of severe neurological disorders models. Neural stem cell biology can be considered 
nowadays a solid research field, which integrated within the gene delivery and regenerative 
medicine fields certainly withholds a promising future. 
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Supplementary figure S1 - Sequencing results, showing 738 matching nucleotides, confirming correct 
cloning of the desired gene into the pcDNA3.1 plasmid. BDNF nucleotide sequence is highlighted in blue. 
23 nucleotides are missing in the sequencing results due to incomplete sequencing. By using a reverse 
primer with a sequence downstream of BDNF we were able to confirm the correct type of the 
initial base pairs. Both primers were designed by the company StabVida® according to the type 
XXIII 
 
of plasmid in use (pcDNA3.1). The obtained sequence perfectly matched with the sequence 
showed below that was provided by the supplier company (Origene®). 
  
 
 
 
 
BDNF nucleotide sequence 
 
5´ATGACCATCCTTTTCCTTACTATGGTTATTTCATACTTTGGTTGCATGAAGGCTGCCCCCATGAAAGA
AGCAAACATCCGAGGACAAGGTGGCTTGGCCTACCCAGGTGTGCGGACCCATGGGACTCTGGAGAG
CGTGAATGGGCCCAAGGCAGGTTCAAGAGGCTTGACATCATTGGCTGACACTTTCGAACACGTGATA
GAAGAGCTGTTGGATGAGGACCAGAAAGTTCGGCCCAATGAAGAAAACAATAAGGACGCAGACTTGT
ACACGTCCAGGGTGATGCTCAGTAGTCAAGTGCCTTTGGAGCCTCCTCTTCTCTTTCTGCTGGAGGAA
TACAAAAATTACCTAGATGCTGCAAACATGTCCATGAGGGTCCGGCGCCACTCTGACCCTGCCCGCC
GAGGGGAGCTGAGCGTGTGTGACAGTATTAGTGAGTGGGTAACGGCGGCAGACAAAAAGACTGCAG
TGGACATGTCGGGCGGGACGGTCACAGTCCTTGAAAAGGTCCCTGTATCAAAAGGCCAACTGAAGCA
ATACTTCTACGAGACCAAGTGCAATCCCATGGGTTACACAAAAGAAGGCTGCAGGGGCATAGACAAA
AGGCATTGGAACTCCCAGTGCCGAACTACCCAGTCGTACGTGCGGGCCCTTACCATGGATAGCAAAA
AGAGAATTGGCTGGCGATTCATAAGGATAGACACTTCTTGTGTATGTACATTGACCATTAAAAGGGGA
AGA 3´ 
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Supplementary figure S2 - Flow cytometry profiles of the ReN cells transfected with GFP at different time 
points, using the wider gate.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure S3 - Flow cytometry profiles of the ReN cells transfected with GFP at different time 
points, using the smaller gate.   
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Supplementary figure S4 - Fold-increase in BDNF expression at the 3
rd
 day of culture, using a Ct of 23.3 
(A) or a Ct of 18.8 (B). Both Ct values were returned in the same experiment within one sample, although 
none were used to prevent an inaccurate analysis. 
 
 
 
A  B  
 
Supplementary figure S5 - Fold-increase in IL-6 expression at the 1
st
 day of culture, using a Ct of 38.3 
(A) or a Ct of 32.6 (B). Both Ct values were returned in the same experiment within one sample, although 
none were used to prevent an inaccurate analysis. 
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